

Enteric Nervous System

Subjects: **Microbiology**

Contributor: Rita Moretti

The gastrointestinal tract has the function of digesting food, absorbing the nutrients, and forming a barrier against harmful agents, but it is also an immune-hormonal system. Functional aspects of this system, such as peristaltic movements, substance transport, and local blood flow, are regulated by an intrinsic network of neuronal ganglia known as the enteric nervous system (ENS). The ENS provides motor excitatory neurons, innervate muscle layers, secretory glands, and the lymphatic vascular system. It is the largest and most complex part of the peripheral nervous system, being organized into distinct neuron networks within the gut wall, where individual small ganglia are interconnected by dense fiber bundles. These nerve plexuses are organized into two layers of neuronal ganglia and enteroglial cells that are interconnected: The myenteric plexus (Auerbach plexus) and the submucosa plexus (Meissner plexus). The ENS forms a complete sensory-motor reflex composed of intrinsic primary afferent neurons (IPANs), interneurons, and motor neurons.

enteric nervous system (ENS)

microbiota

1. The Enteric Nervous System and the Gut–Brain Axis

These plexuses are located between the layers of the gastrointestinal tract and present about 20 subtypes of neurons, differentiated by the expression of neuropeptides ¹. The ENS also features enteroglial cells (EGCs). These are relatively small, with a star shape and can be identified immunochemically through the expression of specific proteins, such as glial fibrillar acid protein (GFAP), vimentin, and S-100 ². These cells can express receptors for cytokines, neuropeptides, and neurotrophins, exerting functions in both the ENS and the immune system, and participating in the modulation of motility and secretion functions of the gastrointestinal tract. In addition, EGCs are necessary for the structural and functional integrity of the ENS, participating in the intestinal mucosal barrier and contributing to intestinal homeostasis ³.

In 2013, the National Institute of Mental Health launched a project focused on exploring the mechanism involved in gut–brain communication ⁴; however, the exact mechanisms by which the gut and brain communicate and influence each other are not yet fully understood. From an anatomical point of view, the critical interactive communications between the gut and brain are the sympathetic system (SS) and the vagus nervus (VN) of the autonomic nervous system (ANS), while the site of interactive communication occurs in the spinal cord ⁴; a sophisticated and four-leveled control system has been well-described ^{5|6}. The very first level occurs in the ENS, where it depends on the myenteric ganglia, sub-mucosae ganglion, and EGCs ^{7|8}. Proceeding in an ascending pathway, the second control step occurs in the prevertebral ganglia, which mediates visceral reflex responses ⁹. The third hierarchical level is located in the spinal tract between T5 and L2, for the SS, and S2 and S4/S5 for the

parasympathetic system, through the tractus solitaires nucleus in the brain stem and the dorsal motor nucleus of VN, whose effect is dominant in the upper gastrointestinal tract, mediated by cholinergic inputs [10]. Cortical and basal ganglia neurons maintain the highest level of control. The afferent fibers of the VN arrive at the nucleus of the tractus solitaires, whose fibers ascend towards the thalamus. Spinal afferent fibers ascend within the spinothalamic tract, enter the gracile nucleus and cuneate nucleus, and project to the thalamus through the lemniscus medialis. These fibers arrive diffusely in the lobus limbicus, which is the insular cortex, through the parabrachialis nucleus [5][11]. The VN represents the primary neural pathway connecting the gastrointestinal tract to the solitary tract's nucleus and from that to the hypothalamus and neocortex [12]. The VN does not directly interact with the gut luminal content [13], despite being indirectly related through metabolites altered by the entero-endocrine cells in the gut epithelium [13]. This system has recently been described, with a complicated relationship between vagal synaptic afferents and entero-endocrine cells in the gut, which probably directs nutritional information towards the brain, mediated by the glutamatergic neurotransmission [14]. VN fibers are enriched with receptors such as 5-HT3, Toll-like receptor 4 (TLR4), and free fatty acid receptors (FFARs), and their final projections end in the brain [13].

In the gastrointestinal tract, a wide variety of neurotransmitters, neuro-regulators, and hormones play different roles. Acetylcholine (ACh) acts via muscarinic receptors to directly stimulate smooth intestinal muscle contractility [15]. Substance P (SP), neurokinin A, and neurokinin B are neuromodulators of tachykinin, and the action of SP on neurotransmission occurs in the non-adrenergic/non-cholinergic system (NANC), which is directly involved in the perception of painful stimuli. The vasoactive intestinal peptide (VIP) induces vasodilation and modulates mucin secretion and the proliferation of goblet cells in the intestinal mucosa [16]. In addition, it participates in the relaxation of intestinal smooth muscles and modulates functions of the lymphocyte component of the immune system. Cholecystokin (CCK) is a major mediator of gastrointestinal feedback to the central nervous system through the afferent component of the VN. Histamine and serotonin (5-hydroxytryptamine or, simply, 5-HT) modulate the function of a variety of intestinal cells, including neurons, EGCs, muscle cells, and the immune system. Somatostatin (SST), which lies behind the regulation of the growth of intestinal cells, inhibits the secretion of gastrin, insulin, glucagon, and cytokines [17][18].

2. Commensal Bacteria and the Enteric Nervous System

The human gastrointestinal system is inhabited by a large group of 1000 distinct species of bacteria in a symbiotic relationship [19]. This variegate collection of microbes is called the “microbiota”, whereas their genetic material is referred to as the “microbiome” [19]. The commensal microbiota colonizes the mammalian gut and other body surfaces shortly after birth and remains there throughout an individual's lifetime. In healthy adult individuals, the microbiota is primarily composed of five bacteria phyla: Firmicutes (79.4%); Bacteroidetes (16.9%); Actinobacteria (2.5%); Proteobacteria (1%); and Verrucomicrobia (0.1%) [20]. Although bacteria are the most represented biological entities, fungi, archaea, and viruses create the “rare biosphere” of the gut microbiome. A healthy and balanced state marked by a high diversity and abundance of microbial populations in the gut is defined as *eubiosis* [19]. A wide range of factors, including diets with highly processed foods, a lack of regular sleep, and several diseases, can alter the microbiota diversity and abundance (*dysbiosis*) [19]. The dysbiotic state has been linked to

several pathological conditions, such as cardiovascular disease, obesity, diabetes, inflammatory bowel disease, and pulmonary hypertension [19][21].

It has long been thought that the only control exerted by the gut microbiota occurs through the VN and ENS [25][26]. Surprisingly, it has been demonstrated that, even though VN and ENS are fundamental in the gut–brain axis, the microbiota plays a critical role in immune, endocrine, and neuroendocrine maturation in nervous system sprouting [25]. It is interesting to note that all of the actors (VN, ENS, and microbiota) are co-primary in their contribution to brain afferents. For example, the capacity of the bacterium *Lactobacillus rhamnosus* JB-1 to modulate anxiety-like behavior and gamma-aminobutyric acid (GABA)-mediated neurotransmission in mice is lost after vagotomy, and the anxiolytic effect produced by *Bifidobacterium longum* NCC3001, which is absent in mice after vagotomy, suggests a fundamental role of the VN and ENS in the modulation of bacteria [27][28]. On the other hand, a mild gastrointestinal infection, after vagotomy, generates anxiety, with a presumed direct effect in the brain [29].

The gut microbiota synthesizes different metabolites, i.e., esters, serotonin, tryptophan, and various fatty acids, which might influence the brain. It has been demonstrated that the indirect effect exerted by the gut microbiota influences serotonergic transmission, regulating tryptophan, whose concentration is higher in male germ-free mice compared to controls with an intestinal microbiota [30], who also show a higher hippocampal concentration of serotonin [14].

It has been well-demonstrated that the microbiota produces short-chain fatty acid (SCFA) metabolites, i.e., butyrate, propionate, and acetate. They have a direct effect on repairing microglia in germ-free mice [31][32]. Furthermore, SCFAs impact at least two systems of molecular signaling that have widespread regulatory effects throughout the body: Histone deacetylation (HDAC) and G-protein-coupled receptors (GPCRs) [33]. SCFAs are natural inhibitors of HDAC and activators of specific G-protein-coupled receptors (GPCRs). An imbalance in the direction of excessive HDAC has been found in Parkinson's disease [34]. GPCRs are transmembrane proteins that represent a significant gateway through which cells convert external cues into intracellular signals [29]. SCFAs activate two specific GPCRs (GPR41 and GPR43) with no other known ligands [35][36]. GPR41 is abundant in human sympathetic ganglia, where its activation by propionic acid increases sympathetic nervous system outflow and one potential mechanism by which dietary fiber (rich in SCFA) can increase the basal metabolic rate and help control obesity [36][37]. It has also been proven that propionate and butyrate administered to rat neuroblasts increased the expression of tyrosine hydroxylase, which is the rate-limiting enzyme in noradrenaline, and dopamine synthesis [14][38]. The main findings in terms of the bacterial influence on the ENS are reported in [Table 1](#) and represented graphically in [Figure 1](#).




Figure 1. The enteric nervous system and the central nervous system constantly communicate with each other and alterations of the microbiota can be involved in the pathogenesis of several diseases.

Table 1. Bacteria and the enteric nervous system.

| Field of Interest | Key Findings |
|--------------------------------|--|
| Gut Microbiota | |
| Social behavior | <p>Social events allow horizontal transmission of microbes between individuals of the same species (as observed in <i>Blattodea</i> or baboons).</p> <p>Rodent models with high-fat diets and reduction of <i>Lactobacillus</i> spp. give birth to offspring with reduced ability to discriminate between familiar and unknown individuals of the same species.</p> <p>Dysbiosis promotes drastic changes in social behavior in rodents and supplementation with <i>Bifidobacteria</i> and <i>Lactobacilli</i> leads to improvement in early life and adulthood.</p> |
| Sleep cycle and mood disorders | <p>Gut microbiota can alter sleep cycles through the systemic production of inflammatory cytokines, which have been proven to alter non-REM sleep and alter cortisol and norepinephrine production. These phenomena are related to gut permeability and systemic translocation of gut bacteria.</p> |
| Alzheimer's disease (AD) | <p>Several bacteria promote neuro-inflammatory response typical of AD.</p> <p>Increased phosphorylated tau in patients with microbiota metabolites in cerebrospinal fluid.</p> |
| Parkinson's disease (PD) | <p>High microbial density in the olfactory bulbs of patients with PD.</p> <p>Postural instability and gait symptoms can be associated with abundance of particular species.</p> |

| Field of Interest | Key Findings |
|--------------------------|--|
| | Gut Microbiota |
| Toxin-producing bacteria | Pathogenic bacteria Toxin-induced diarrhea is favored by the promotion of serotonin (5-HT) from the mucosa, resulting in activation of the secretomotor reflex pathways through local 5-HT receptors. In cases of emesis, 5-HT receptors are located in vagus nerve (VN) sensory terminals that project up to the emetic center in the brainstem. |

2.1. Microbiota and Social Behavior

Given the broad abundance of information on the topic of interactions between bacteria (being pathogens or commensal bacteria), only key findings have been reported. Different studies have remarked on the fundamental role of the gut microbiota in social behavior. This probably involves the horizontal transmission of microbes between conspecifics [14], for example, in specific Blattodea, through social events such as coprophagia and proctodeal trophallaxis or in social bees [39]. The presence of *Bifidobacterium* and *Lactobacillus* in their gut is fundamental for SCFA production, which becomes essential for nutrition in starvation periods [40][41]. Different social behavior, such as grooming, in Baboons, is determined by the convergence of core gut microbial taxa [42]. The data seem even more impressive when considered that mice born from mothers on a high-fat diet present an altered microbiota composition, with a significant reduction of *Lactobacillus* spp. and a reduced ability to discriminate between familiar and unknown conspecifics [43]. This defect can be replaced by *Lactobacillus reuteri*, with a consequent increment of oxytocin, in the paraventricular nucleus of the hypothalamus [44], improving their social conduct [14].

Alterations of the gut microbiota, associated with a lack of expression of Toll-like receptors (TLRs), contribute to the altered response of different pathogens in the gut, i.e., a TLR4-knockout mouse does not show any response to lipopolysaccharide (LPS) produced by gram-negative bacteria [45][46]. The Griseofulvin Mouse model, compared with a specific-pathogen-free mouse model, produced significantly elevated corticosterone and adrenocorticotropic hormone levels when exposed to stressful conditions. This production could be partially reversed by a fecal microbial transplant, and was ultimately reversed over time by single *Bifidobacterium infantis* [47]. Moreover, the experimental conditions reveal that, on that occasion, the timing of the microbiota modeling answer is very limited in time-span, being fundamental for a precocious maturation of the hypothalamus–pituitary–adrenal axis, with a gender-specific response [31][48]. More recently, many studies have documented that the microbiota of long-term stressed mice was significantly different from that of a non-stressed mouse [49]. One study also showed that prolonged stress reduces the quantity of *Bacteroides* at the cecum and increases the amount of *Clostridium* [49]. Namely, three kinds of stress-induced bacteria of *Enterococcus faecalis*, *Pseudobutyribrio*, and aerogenic bacteria of the *Dorea* strain have been found [5][49].

Experimental models of germ-free and antibiotic-treated animals, both of which determine a total absence of microbiota, show macroscopic alterations of neurotransmitter turnover, an altered neuronal morphology, and significant neuroinflammation [49], depending on the time of microbiota onset. Likewise, a substitution of the microbiota results in a drastic modification of behavior and social conduct in experimental animals, such as rodents. On the contrary, supplementation with *Bifidobacterium* and *Lactobacillus* can lead to notable improvements in social behavior in early life and adulthood [14]. As admirably written by Sherwin et al. [14],

“Emerging research is now conceptualizing animals as “holobionts”: dynamic ecosystems, comprising a host and its associated microorganisms, that can vary with time, localization, and function. Collectively, the host and microbial genomes of a holobiont are termed a hologenome, and variations in the hologenome caused by changes in the host and/or microbes may affect phenotypes may be subject to natural selection”.

2.2. Microbiota, Sleep Cycle, and Mood Disorders

According to Sherwin et al. [14] and many others [44][50][51][52][53][54][55][56][57][58][59][60], it seems quite essential that the microbiota persistently stimulates the immune system, but this remodeling effect has a consequence, even if very distant [37][59]. A possible interface between the gut microbiota and sleep regulation has been suggested. It has been widely described that the gut microbiome produces and activates intestinal macrophages, inducing the production of IL-1 β and TNF- α [60]; inside the intestinal wall, many LPS induce the synthesis of IL2-IL18 [61][62][63]. The intimate relationship between TNF- α , IL-18, and NREM sleep has been described [62][63]. It is also well-accepted that cortisol inhibits the synthesis of these cytokines in the gut-microbiota, and IL-1 β and TNF- α display a peak level in human blood around midnight, when cortisol is at the nadir [64][65]. The parenteral administration of LPS to humans in nanogram quantities (0.4 ng/kg body weight) increases the plasma concentration of IL-6 and TNF- α , along with salivary and plasma cortisol and plasma norepinephrine. These changes are accompanied by a depressed mood, increased anxiety, and impaired long-term memory for emotional stimuli [66][67]. Matsuda et al. recently developed a depression rat model using the 14-day social defeat stress (SDS) paradigm [68]. These experimental rodents exhibit long-term social avoidance, major depressive disorders, and sleep abnormalities, with increased REM, but a decreased NREM sleep time and increased defragmentation of sleep continuity. The authors examined the fecal gut microbiota before, during, and after stress studies. The social defeat stress significantly increased the fecal classes of Betaproteobacteria and Flavibacteria, while decreasing those of Clostridia. *Bacteroides* and *Bacilli* showed a tendency to increase, whereas *Actinobacteria* tended to decrease. When compared to before stress, *Lactobacillus* showed evident decreases, whereas *Blautia* exhibited significant increases. The *Lactobacillus reuteri* levels significantly increased following stress conditions, with further increases observed even being observed one month after the stress conditions ended [68]. Conversely, other species (*Ruminococcus flavefaciens*, *Blautia producta*, and *Clostridium perfringens*) exhibited only temporary change [67][68].

It has been demonstrated that an altered gut-microbiome with elevated LPS and peptidoglycan is regularly higher than that of a teetotaler; in alcoholics, before and during ethanol detoxification, there is an increased mRNA and plasma level of IL-8, IL-1 β , and IL-18. Employing Cr51-EDTA as a probe of intestinal permeability, a population of chronic alcoholics was studied, who were divided into two groups: Those with high and those with normal permeability (65). The high permeability group had higher scores of depression, anxiety, and alcohol craving than the low permeability group, as well as a distinct pattern of changes in the gut microbial population, characterized by decreased colonization of bacteria known to have anti-inflammatory effects; *Bifidobacterium* species; and *Faecalibacterium*, in particular, *Faecalibacterium prausnitzii* [37][69]. Alcoholics who displayed the persistence of intestinal hyper-permeability after three weeks of ethanol withdrawal also demonstrated the persistence of depression, anxiety, and alcohol craving [69].

2.3. Microbiota and Alzheimer's Disease

Alzheimer's disease (AD) is a chronic and irreversible neurodegenerative disease, characterized by a loss of neurons and progressive impairments in the synaptic function, accompanied by deposition of the amyloid- β (A β) peptide outside or around neurons, together with an accumulation of hyper-phosphorylated protein tau inside cortical neurons [69][70][71][72][73]. Amyloid accumulation, involving the deposition of hyperphosphorylated tau proteins, with consequent microtubule destabilization, leads to two critical processes: An essential increase of general neuro-inflammation, and significant microglial and astrocytic activation and starvation of the neurons, due to the interruption of axonal transport. The most important consequences are the altered glutamatergic currents and the critical calcium inflow currents, with the significant induction of apoptosis [72][73][74][75][76]. Animal models of amyloid and tau depositions are related to herpes simplex virus type 1 (HSV1) infection in mice that upregulates the encoding genes for cholesterol 25-hydroxylase (CH25H), which seems to be involved in amyloid altered catabolism or hyper-production [77][78][79]. Nevertheless, many other bacteria have been related to the essential neuro-inflammatory status, typical of AD, such as spirochaete, and *Chlamydia pneumoniae* [77][80][81]. A positive relationship with phosphorylated tau and phosphorylated tau/Abeta 42 in cerebrospinal fluid and microbiota metabolism has been found with an elevation of trimethylamine N-oxide in AD models [82]. Moreover, transgenic wild-type amyloid precursor protein (APP) mice and germ-free mice have a diminished level of amyloid deposition compared to APP mice with a healthy microbiota [83], and this has also been proved in long-term spectrum antibiotic treatment, which seems to reduce amyloid depositions [84]. It has been described that AD mice have severe quotes of Verrucomicrobia and Proteobacteria, with a concomitant reduction of *Ruminococcus* and *Butyricicoccus* and short-chain fatty acids [85][86]. Moreover, poor oral hygiene has been linked to AD, with parodontopathy and tooth loss being risk factors for dementia in two studies [87][88], as well as severe periodontitis related to lower cognitive functions [89][90][91][92][93][94][95][96]. Even if studies have many different biases, it has been demonstrated that periodontal disease may be related to an increased brain amyloid load through PET studies [92], and that there is an increase of Fusobacteriaceae and higher abundance of Prevotellaceae in AD patients [92][97].

2.4. Microbiota and Parkinson's Disease

More studies have been conducted on the second most frequent form of neurodegenerative disease, which is Parkinson's Disease (PD). The converging line of these studies shares two common points: The high-density microbial population of the olfactory bulb and the gut, and the high-density deposition of misfolded alpha-synuclein deposition at the two sites [12][98][99][100]. It has been demonstrated that the alpha-synuclein deposits have a rostrocaudal gradient [101], with a higher concentration in the submandibular gland and lower concentration in the esophagus [101][102]. It has been suggested that the main vagal efferents could be the sprouting routes from peripheral sites towards the brainstem [99], and a vagotomy decreased the adjusted risk of developing PD in a 20-year-followed-up population [103][104]. It has been demonstrated that there is a higher intestinal permeability in PD patients [105], with a higher presence of Enterobacteriales (*E. coli*) in mucosal staining, associated with a higher plasmatic LPS binding protein in PD patients [101][102]. In wild-type over-expressed alpha-synuclein mice (ASO), germ-free conditions produce fewer motor symptoms and minimal signs of general brain inflammation and alpha-synuclein [106]. The same aspects occur in antibiotic-treated mice, whereas colonization with wild-type mice or

healthy subjects feces, or with high quantities of SCFAs, determines a worsening of Parkinsonian motor symptoms [105]. Three cross-sectional studies reported a relative abundance of Prevotellaceae in PD, but not in controls [107]. Combined with the severity of constipation, the abundance of Prevotellaceae, Lactobacillaceae, Bradyrhizobiaceae, and Clostridiales IV could be used to identify PD cases with a 66.7% sensitivity and 90.3% specificity. Postural instability and gait symptoms were associated with the relative abundance of Enterobacteriales [101][107][108]. It has also been reported that there is an increment of LPS synthesis in PD subjects relative to controls [108]. The same aspect has been reinforced in a different study, which showed lower serum levels of LPS-binding protein [109], as well as a reduction of the absolute concentration of fecal SCFAs (acetate, propionate, and butyrate) [110].

2.5. Microbiota and Other Neurodegenerative Disease

Several studies in animal and human models of demyelinating diseases, i.e., experimental autoimmune encephalomyelitis (EAE), Multiple Sclerosis (MS), and Devic's Neuromyelitis (NMO), have been performed [111][112][113][114][115].

Germ-free mice were highly resistant to developing autoimmune encephalitis [112][113] or had lower clinical scores due to their encephalitis [113]. However, this condition was acutely reversed when these germ-free mice received a fecal transplant from healthy mice [115]. It has been thought that environmental conditions which seem to influence MS progression, such as obesity, smoking, low vitamin D levels, and altered responses to human viruses [23][116][117][118][119], seem to do so through the mediation of microbiota [120][121]. Leaky gut [122] is highly present in relapsing-remitting MS, and different studies have shown a different gut microbiota composition in MS, rather than in control subjects [122][123][124][125][126][127]. Any specificity has been remarked on for a given microbiota composition in MS cases, but a pro-inflammatory milieu is a constant finding [101][122]. Overlap with other inflammatory chronic conditions, such as Crohn's disease, small intestinal bacterial overgrowth, rheumatoid arthritis, and undifferentiated connective pathologies, has been documented [128][129][130]. There is a tendency to report some specific groups of microbes in MS microbiota, i.e., Archaea (genus *Methanobrevibacter*) [124], or the depletion of Firmicutes species (*Clostridium* genera) [122] and Bacteroidetes phyla [125][126][127]. Even animal models of EAE (primates) might show low levels of Lipid 654, which is a lipopeptide, presumably derived from gut Bacteroidetes [131]. Minimal studies have been done to determine MS levels and disease-progression, and a definite result could be obtained through such investigations. Nevertheless, in a pediatric MS population, the depletion of Fusobacteria was associated with a higher hazard ratio of an earlier relapse [122], and different studies are currently being conducted on this fascinating topic [132].

The scenario for NMO is different, which is frequently associated with anti-aquaporin4 and the presence of the *Clostridium* adenosine triphosphate-binding cassette transporter in the gut microbiota [133][134], even if all recruited patients with NMO undergo Rituximab therapy [134][135].

3. Pathogenic Bacteria and the Enteric Nervous System

In addition to commensal microbiota, pathogenic bacteria in the lumen also interact with the ENS indirectly through non-neuronal intermediary cells, such as endocrine (in particular, enterochromaffin cells (ECs)) or immune resident gut cells. Some enterotoxins evoke intestinal secretion via nervous reflexes, occurring in parallel to toxins and having a direct secretive effect on intestinal cells.

In addition, a local gut infection can lead to subtle changes in the affective state and emotional responsiveness, as in the case of *Campylobacter jejuni* rodent models, which developed anxiety-like behavior in the absence of a systemic immune response. In particular, *Campylobacter jejuni* infection was associated with an elevated expression of the neuronal activation marker c-Fos in neurons located in the vagal sensory ganglia and in the nucleus of the solitary tract, as well as in brain regions associated with primary viscerosensory pathways and the central autonomic network [136].

3.1. Toxins Promoting Secretion

Among toxin-producing bacteria, *Vibrio cholerae* produces a potent exotoxin which causes hypersecretion in the small intestine. The cholera toxin (CT) consists of an A (or enzymatic) subunit of 28 kDa, and five B (or binding) subunits of 11 kDa each, assembled in a pentameric molecule. The implication of ENS in the pathophysiology of cholera infection was initially proposed in 1980 [137]. Previous evidence suggested that CT activated persistent cAMP-dependent release of 5-HT from the mucosa, resulting in activation of the secretomotor reflex pathways (via the 5-HT₃ receptor) in the ENS by the activation of dendrites of submucosal plexus neurons, and eventually resulting in the release of VIP and its binding to enterocytic receptors, thus activating further cAMP production, promoting water and electrolyte secretion [20][138]. However, recent evidence suggests that CT increases the excitability of neurons of the myenteric, but not submucosal, plexus, and that neurokinin 3-receptors and not 5-HT₃ receptors are involved in the neurosecretory reflex [139]. The heat labile enterotoxin (HLT) produced by *E. coli* shares a structural homology of 88% with the CT and induces a much less severe form of diarrhea [140]. Moreover, HLT inoculation does not stimulate the release of 5-HT from ECs. The HLT mechanism appears to be intricately related to the ENS, given that the administration of ganglionic blockers had preventive effects on the development of diarrhea [140]. Furthermore, the much smaller *E. coli* heat-stable enterotoxins (STa) of 2-5 kDa seem to activate an NO-dependent myenteric plexus secretory reflex mediated by capsaicin-sensitive C fibers [141][142], in addition to response suppression by VIP antagonists. In this case, VIP and NO appear to have a synergistic effect, since NO promotes VIP secretion from nerve terminals. In addition, STa can activate neurokinin receptor 2, which can further promote intestinal secretion [143].

Clostridioides difficile, which is another toxigenic bacterium, is the primary cause of antibiotic-associated diarrhea and colitis in humans. Toxigenic strains release two exotoxins: Toxin A (TX-A) and (TX-B). These are responsible for diarrhea and an acute mucosal inflammatory response [144]. The introduction of *C. difficile* toxins into the gut lumen stimulated the influx of neutrophils and promoted the activation of enteric neurons to increase luminal secretion and peristalsis [145]. Additionally, responses to TX-A involve the up-regulation of substance P in both lumbar dorsal root ganglia and small bowel enterocytes [146]. In addition, in vivo models showed that low doses of TX-A solicited an excitatory action at the level of the submucosal plexus and were involved in the suppression of

noradrenaline release from sympathetic postganglionic axons [147]. As a result, the stimulation of submucosal secretomotor neurons evokes secretion from mucosal crypts. The inactivation of sympathetic braking on secretomotor neurons further facilitates the secretion. Moreover, recent studies showed that EGCs are susceptible to *C. difficile* infection, due to the cytotoxic and senescence-promoting effects of TX-B [148][149].

3.2. Toxins Promoting Emesis

Staphylococcus aureus produces a myriad of enterotoxins (SEs), commonly responsible for food poisoning. It appears that emesis is caused by 5-HT secretion. In particular, it may be related to 5-HT3 receptors located in VN sensory terminals that project up to the emetic center in the brainstem [150]. However, the process has only been proven indirectly in animal models of *Suncus murinus*, given that emesis is prevented by 5-HT inhibitor and 5-HT3 receptor antagonists [151]. A similar mechanism has been proposed for cereulide, which is a cyclic dodecadepsipeptide that is produced by *Bacillus cereus*. The emetic effects of the toxin seem to be dependent on 5-HT3 receptors on VN afferent neurons since vagotomy and 5-HT3 receptor antagonists inhibit emesis in *Suncus* [152]. Similar to SEs, it is not known whether cereulide directly interacts with VN sensory endings or promotes 5-HT release by ECs [152].

4. Viral Influence on the Enteric Nervous System

Several gastrointestinal motility disorders (GIMDs) can depend on functional or anatomic alterations of the ENS [153][154][155]. The molecular basis of these alterations is heterogeneous, including degenerative and inflammation-mediated abnormalities [156]. In this context, infectious agents, such as neurotropic viruses, can be identified as etiological factors affecting the integrity of the ENS, either directly or through immune-mediated mechanisms [156]. The main findings in terms of the viral influence on the ENS are reported in [Table 2](#) and represented graphically in [Figure 2](#).




Figure 2. Pathogenic bacteria, viruses, and parasites primarily affecting the gastrointestinal system interact with the enteric nervous system, establishing a connection between the gut and the central nervous system.

Table 2. Viruses and the enteric nervous system.

| Viral Agent(s) | Pathogenetic Mechanism(s) | Disease(s) |
|--------------------------|--|--|
| TBEV | Myenteric plexus infection | Irreversible ileus |
| WNV, ZIKV | Viral replication within enteric neurons causing cell death | Intestinal dysmotility |
| Influenza A virus/HSV-1 | Influenza A virus alterations in the ENS structures, followed by HSV-1 life-long persistency | Parkinson's disease |
| Herpesviruses (EBV, VZV) | VZV latency in ganglia of the ENS; EBV induction of inflammatory infiltrates within the myenteric plexuses | Ogilvie's syndrome, CIPO, myenteric ganglionitis |
| JCV | Infection of the EGCs of the myenteric plexus | CIPO |
| HIV | HIV-1 Tat protein activation of EGCs causing a neuroinflammatory response and synergistic action with morphine | Diarrhea and neurotoxic effects |
| Rotaviruses | Rotavirus infection of the EC cells and stimulation of serotonin secretion | Rotavirus-related diarrhea |

| Viral Agent(s) | Pathogenetic Mechanism(s) | Disease(s) |
|----------------|---|---|
| HAdV-41 | Serotonin release from EC cells leading to activation of EGCs | Diarrhea |
| HSV-1 | Destruction of the enteric neurons by the massive recruitment of neutrophils | Loss of peristalsis and toxic megacolon |
| SARS-CoV-2 | Activation of EGCs with massive release of IL-6 and other inflammatory mediators (cytokine storm) | SARS-CoV-2 related-diarrhea |

Evidence supporting viruses as possible etiological factors involved in GIMDs is still based on sporadic cases or small case series reporting the occurrence of viremia (e.g., polyomaviruses, influenza, and herpes zoster) before the onset of a malabsorption [157].
 WNV: West Nile Virus; ZIKV: Zika Virus; HSV-1: Herpes Simplex Virus 1; EBV: Epstein-Barr Virus; VZV: varicella-zoster virus; JCV: John Cunningham Virus; ECs: enterocytes; GIPO: chronic intestinal idiopathic pseudo-obstruction; HADV-41: Human Immunodeficiency Virus; EC cells: enterochromaffin cells; HAdV-41: Adenovirus-41.

Viruses can target different cellular populations of the ENS. The EGCs are the major component of the ENS that can be targeted by viruses and outnumber enteric neurons by a factor of 4 to 10 [161]. EGCs act as a mechanical support for enteric neurons, are responsible for the survival and differentiation of neurons [162], and are antigen-presenting cells to innate and adaptive immune cells [163][164]. Then, EGC activation by viruses or their antigens is a key step for peripheral neuroglial immune priming by viruses, leading to a late onset of neurological impairment [165]. Inflammatory stimuli activate EGCs and convert them into a “reactive glial cell phenotype” which can release protective factors (neurotrophin-3, GDNF, GNSO, and PEA/PPAR- α) or destructive factors. The massive release of destructive factors and several proinflammatory mediators, such as IL-1 β , IL-6, TNF- α , and MCP-1, alters the gastrointestinal motility [166][167][168].

Some cases of intestinal dysmotility disorders seem to be related to viral infection [169][170][171]. In mice models, inoculation with neurotropic flaviviruses leads to the injury and death of enteric neurons, inflammation, intestinal dilation, and retarded bowel transit. More precisely, the inoculation of mice with the flaviviruses West Nile virus (WNV) and Zika virus (ZIKV) leads to viral replication throughout the intestinal tract and the dilation of intestinal segments. Viral replication has been specifically observed within enteric neurons, causing cell death, but not in glial cells or mucosal epithelial cells. In addition, animals surviving WNV infection show defects in gastrointestinal motility from 4 to 7 weeks after infection. Overall, these observations support the hypothesis that some gastrointestinal dysmotility disorders may be episodic following infection/inflammation or chronic, which can be periodically exacerbated by additional infections or inflammation [172].

A delayed effect of viral infection can be hypothesized in the initial neuropathogenesis of Parkinson's Disease, according to the "viremic hit" hypothesis, which is based on a dual-hit theory. In particular, influenza A virus may "hit and run", initiating pathological alterations in the ENS structures, whereas HSV-1 may "hit" and establish life-long persistency with repetitive reactivations from latency, depending on the level of immunosenescence [173]. These viremic hits might induce the formation of α -synuclein fibrils in the peripheral nervous tissues, leading to the gradual transneuronal propagation of α -synucleopathy within the brain [174][175][176].

Additional neurotropic and gastrointestinal tract-infecting viruses should be considered as good candidates for causing human gastrointestinal dysmotility disorders. In this regard, some cases of chronic intestinal idiopathic pseudo-obstruction (CIPO) [177] have been associated with viral infections in both pediatric [178][179] and adult patients [158][180][181]. Among the candidate infectious agents, herpes family virus, varicella zoster virus (VZV), cytomegalovirus (CMV), Epstein–Barr virus (EBV), and JC virus infections have been identified. Basically, it is believed that viral infections can affect the neuromuscular layer of the gut. In particular, VZV may infect and establish latency in ganglia of the ENS [156] and it has been associated with acute colonic pseudo-obstruction (Ogilvie's syndrome), severe abdominal pain preceding fatal varicella, autonomic dysfunction, and intestinal pseudobstruction symptoms following glandular fever secondary to EBV infection [179]. In comparison, EBV has been associated with myenteric ganglionitis, characterized by inflammatory infiltrates within the myenteric plexuses [179]. JC virus has been identified in the enteroglial cells of the myenteric plexus in some patients with CIPO [182].

EGCs have also been identified as an HIV target. The viral HIV-1 Trans activating factor (HIV-1 Tat) protein is hypothesized to be responsible for diarrhea and neurotoxic effects. One hypothesized mechanism is that HIV-1 activates glial cells, causing a neuroinflammatory response, which can be propagated to the central nervous system. Specifically, HIV interferes with the nervous system function by infecting EGCs, which release HIV-1 Tat, inducing an alteration in enteric neurons' action potential by increasing Na^+ channel expression [165][183]. In addition, Tat can interact synergistically with morphine, being able to activate EGCs and worsen GI dysfunction in HIV-infected narcotic users and HIV-infected patients, using opioid drugs to treat diarrhea [184][185]. Other interactive pathways have been shown between HIV-1 Tat protein and LPS. In mice models expressing Tat, bacterial intestinal translocation is significantly increased. Consequently, Tat and LPS synergize to induce the release of the pro-inflammatory cytokines IL-6, IL-1 β , and TNF- α . More specifically, HIV-1 Tat is able to interact with the TLR4 receptor to enhance the pro-inflammatory effects of LPS [186].

EGCs can be activated by ECs infected with viruses. ECs are distributed along the intestinal mucosa to release mediators from the basolateral surface and to activate afferent neuron endings, mainly within the lamina propria [187]. Among their mediators, ECs release serotonin [188], which activates the ENS and the extrinsic vagal afferents to the brain, and may also activate EGCs [21]. The involvement of serotonin has been demonstrated to play a key role in the regulation of intestinal secretion, gut motility, several GI disorders, nausea, vomiting, and acute gastroenteritis [189][190]. Rotaviruses can infect EC cells and stimulate serotonin secretion in a dose- and time-dependent manner, leading to RV-related diarrhea [191]. Similarly, Adenovirus-41 (HAdV-41) can stimulate serotonin from coxsackievirus and adenovirus receptor (CAR)-expressing human EC cells, activating EGCs. These observations highlight a serotonin-dependent cross talk between HAdV-41, EC cells, and EGCs that may be relevant for understanding how HAdV-41 causes diarrhea [192].

The activation of EGCs has been hypothesized for SARS-CoV-2 related-diarrhea. Indeed, the activated EGCs massively release IL-6 and other inflammatory mediators, resulting in the so-called "cytokine storm" observed in COVID-19 patients. Therefore, in these cases, GI dysfunction may be considered as a possible marker of involvement of ENS/EGC, rather than an accessory symptom, highlighting a pathophysiological mechanism underlying SARS-CoV-2 neuroinvasion [193][194][195][196].

Enteric neurons can be targeted by HSV-1. Once infected, the neurons recruit inflammatory macrophages that, by releasing ROS, induce changes in ENS neuroplasticity and trigger the destruction of the enteric ganglia, causing gastrointestinal dysmotility [197][198]. HSV-1 infection leads to the destruction of the enteric neurons by the massive recruitment of neutrophils, resulting in the permanent loss of peristalsis and the development of a toxic megacolon [171]. Therefore, the acute or chronic exposure of enteric neurons to neurotropic viruses, such as HSV-1, permanently disturbs the interplay between the ENS and immune cells.

The number of viruses physiologically residing in the human intestine is estimated to be up to 10^9 per gram of feces [14], mainly comprising bacteriophages (prokaryotic-infecting viruses), and to a lesser extent, plant-, amoebae-, human-, and other animal-infecting viruses [199]. The human virome is mostly acquired postnatally and is influenced by a combination of dietary, maternal, and environmental sources [200]. During its life course, the virome diversifies and reaches its peak by adulthood [201]. Eukaryotic viruses, such as *Parvoviridae*, *Anelloviridae*, *Picobirnaviridae*, *Circoviridae*, and *Reoviridae*, are often part of the enteric virome of healthy humans [199], despite being opportunistic pathogens. It is not yet understood which viral sensing and signaling pathways are important for adjusting the immune responses to control the abundance and composition of the human intestinal virome.

References

1. Furness, J.B. Types of neurons in the enteric nervous system. *J. Auton. Nerv. Syst.* 2000, **81**, 87–96. [Google Scholar] [CrossRef]
2. Fekete, E.; Timmermans, J.P.; Resch, B.A.; Scheuermann, D.W. Different distribution of S-100 protein and glial fibrillary acidic protein (GFAP) immunoreactive cells and their relations with nitroergic neurons in the human fetal small intestine. *Histol. Histopathol.* 1999, **14**, 785–790. [Google Scholar] [PubMed]
3. Christofi, F.L. TRPV1 Sensory Neurons and Enteric Glia in ENS Link Tachykinins to Neuroinflammation and Nociception. *Cell. Mol. Gastroenterol. Hepatol.* 2018, **6**, 354–355. [Google Scholar] [CrossRef] [PubMed]
4. Wang, H.-X.; Wang, Y.-P. Gut Microbiota-brain Axis. *Chin. Med. J.* 2016, **129**, 2373–2380. [Google Scholar] [CrossRef]
5. Foster, J.A.; Neufeld, K.-A.M. Gut–brain axis: How the microbiome influences anxiety and depression. *Trends Neurosci.* 2013, **36**, 305–312. [Google Scholar] [CrossRef]
6. Mayer, E.A.; Tillisch, K.; Gupta, A. Gut/brain axis and the microbiota. *J. Clin. Investig.* 2015, **125**, 926–938. [Google Scholar] [CrossRef]
7. Schemann, M.; Neunlist, M. The human enteric nervous system. *Neurogastroenterol. Motil.* 2004, **16**, 55–59. [Google Scholar] [CrossRef]

8. Anlauf, M.; Schäfer, M.K.-H.; Eiden, L.E.; Weihe, E. Chemical coding of the human gastrointestinal nervous system: Cholinergic, VIPergic, and catecholaminergic phenotypes. *J. Comp. Neurol.* 2003, 459, 90–111. [Google Scholar] [CrossRef]
9. Szurszewski, J.H. Physiology of Mammalian Prevertebral Ganglia. *Annu. Rev. Physiol.* 1981, 43, 53–68. [Google Scholar] [CrossRef]
10. Chang, H.Y.; Mashimo, H.; Goyal, R.K. Musings on the wanderer: What's new in our understanding of vago-vagal reflex? IV. Current concepts of vagal efferent projections to the gut. *Am. J. Physiol. Liver Physiol.* 2003, 284, G357–G366. [Google Scholar] [CrossRef]
11. Han, W.; Tellez, L.A.; Perkins, M.H.; Perez, I.O.; Qu, T.; Ferreira, J.; Ferreira, T.L.; Quinn, D.; Liu, Z.-W.; Gao, X.-B.; et al. A Neural Circuit for Gut-Induced Reward. *Cell* 2018, 175, 665–678.e23. [Google Scholar] [CrossRef] [PubMed]
12. Sherwin, E.; Bordenstein, S.R.; Quinn, J.L.; Dinan, T.G.; Cryan, J.F. Microbiota and the social brain. *Science* 2019, 366, eaar2016. [Google Scholar] [CrossRef] [PubMed]
13. Bonaz, B.L.; Bazin, T.; Pellissier, S. The Vagus Nerve at the Interface of the Microbiota-Gut-Brain Axis. *Front. Neurosci.* 2018, 12, 49. [Google Scholar] [CrossRef] [PubMed]
14. Gonkowski, S.; Rytel, L. Somatostatin as an Active Substance in the Mammalian Enteric Nervous System. *Int. J. Mol. Sci.* 2019, 20, 4461. [Google Scholar] [CrossRef] [PubMed]
15. Mourad, F.H.; Barada, K.; Rached, N.A.B.; Khoury, C.I.; Saadé, N.E.; Nassar, C.F. Inhibitory effect of experimental colitis on fluid absorption in rat jejunum: Role of the enteric nervous system, VIP, and nitric oxide. *Am. J. Physiol. Liver Physiol.* 2006, 290, G262–G268. [Google Scholar] [CrossRef] [PubMed]
16. De Oliveira, J.A.; Freitas, M.A.R.; De Oliveira, E.C.; Jabari, S.; Brehmer, A.; Da Silveira, A.B.M. 5-HT3A serotonin receptor in the gastrointestinal tract: The link between immune system and enteric nervous system in the digestive form of Chagas disease. *Parasitol. Res.* 2019, 118, 1325–1329. [Google Scholar] [CrossRef]
17. Natale, G.; Ryskalin, L.; Busceti, C.L.; Biagioni, F.; Fornai, F. The nature of catecholamine-containing neurons in the enteric nervous system in relationship with organogenesis, normal human anatomy and neurodegeneration. *Arch. Ital. Biol.* 2017, 155, 118–130. [Google Scholar]
18. Lundgren, O. Enteric Nerves and Diarrhoea. *Pharmacol. Toxicol.* 2002, 90, 109–120. [Google Scholar] [CrossRef]
19. Kim, S.; Rigatto, K.; Gazzana, M.B.; Knorst, M.M.; Richards, E.M.; Pepine, C.J.; Raizada, M.K. Altered Gut Microbiome Profile in Patients With Pulmonary Arterial Hypertension. *Hypertension* 2020, 75, 1063–1071. [Google Scholar] [CrossRef] [PubMed]

20. Kaelberer, M.M.; Buchanan, K.L.; Klein, M.E.; Barth, B.B.; Montoya, M.M.; Shen, X.; Bohórquez, D.V. A gut-brain neural circuit for nutrient sensory transduction. *Science* 2018, 361, eaat5236. [Google Scholar] [CrossRef]
21. Borre, Y.E.; O'Keeffe, G.W.; Clarke, G.; Stanton, C.; Dinan, T.G.; Cryan, J.F. Microbiota and neurodevelopmental windows: Implications for brain disorders. *Trends Mol. Med.* 2014, 20, 509–518. [Google Scholar] [CrossRef]
22. Hagbom, M.; Istrate, C.; Engblom, D.; Karlsson, T.; Rodriguez-Diaz, J.; Buesa, J.; Taylor, J.A.; Loitto, V.-M.; Magnusson, K.-E.; Ahlman, H.; et al. Rotavirus Stimulates Release of Serotonin (5-HT) from Human Enterochromaffin Cells and Activates Brain Structures Involved in Nausea and Vomiting. *PLOS Pathog.* 2011, 7, e1002115. [Google Scholar] [CrossRef] [PubMed]
23. Giuffrè, M.; Campigotto, M.; Campisciano, G.; Comar, M.; Crocè, L.S. A story of liver and gut microbes: How does the intestinal flora affect liver disease? A review of the literature. *Am. J. Physiol. Liver Physiol.* 2020, 318, G889–G906. [Google Scholar] [CrossRef] [PubMed]
24. Davenport, E.R.; Mizrahi-Man, O.; Michelini, K.; Barreiro, L.B.; Ober, C.; Gilad, Y. Seasonal Variation in Human Gut Microbiome Composition. *PLoS ONE* 2014, 9, e90731. [Google Scholar] [CrossRef] [PubMed]
25. Bercik, P.; Park, A.J.; Sinclair, D.; Khoshdel, A.; Lu, J.; Huang, X.; Deng, Y.; Blennerhassett, P.A.; Fahnestock, M.; Moine, D.; et al. The anxiolytic effect of *Bifidobacterium longum* NCC3001 involves vagal pathways for gut-brain communication. *Neurogastroenterol. Motil.* 2011, 23, 1132–1139. [Google Scholar] [CrossRef]
26. Bravo, J.A.; Forsythe, P.; Chew, M.V.; Escaravage, E.; Savignac, H.M.; Dinan, T.G.; Bienenstock, J.; Cryan, J.F. Ingestion of *Lactobacillus* strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve. *Proc. Natl. Acad. Sci. USA* 2011, 108, 16050–16055. [Google Scholar] [CrossRef]
27. Forsythe, P.; Bienenstock, J.; Kunze, W.A. Vagal Pathways for Microbiome-Brain-Gut Axis Communication. *Adv. Exp. Medi. Biol.* 2014, 817, 115–133. [Google Scholar] [CrossRef]
28. Bercik, P.; Verdu, E.F.; Foster, J.A.; Macri, J.; Potter, M.; Huang, X.; Malinowski, P.; Jackson, W.; Blennerhassett, P.; Neufeld, K.A.; et al. Chronic Gastrointestinal Inflammation Induces Anxiety-Like Behavior and Alters Central Nervous System Biochemistry in Mice. *Gastroenterology* 2010, 139, 2102–2112.e1. [Google Scholar] [CrossRef]
29. Clarke, G.; Grenham, S.; Scully, P.; Fitzgerald, P.J.; Moloney, R.D.; Shanahan, F.; Dinan, T.G.; Cryan, J.F. The microbiome-gut-brain axis during early life regulates the hippocampal serotonergic system in a sex-dependent manner. *Mol. Psychiatry* 2013, 18, 666–673. [Google Scholar] [CrossRef] [PubMed]

30. Erny, D.; De Angelis, A.L.H.; Jaitin, D.A.; Wieghofer, P.; Staszewski, O.; David, E.; Keren-Shaul, H.; Mahlakoiv, T.; Jakobshagen, K.; Buch, T.; et al. Host microbiota constantly control maturation and function of microglia in the CNS. *Nat. Neurosci.* 2015, 18, 965–977. [Google Scholar] [CrossRef] [PubMed]
31. Van De Wouw, M.; Boehme, M.; Lyte, J.M.; Wiley, N.; Strain, C.; O'Sullivan, O.; Clarke, G.; Stanton, C.; Dinan, T.G.; Cryan, J.F. Short-chain fatty acids: Microbial metabolites that alleviate stress-induced brain-gut axis alterations. *J. Physiol.* 2018, 596, 4923–4944. [Google Scholar] [CrossRef] [PubMed]
32. Tan, J.; McKenzie, C.; Potamitis, M.; Thorburn, A.N.; Mackay, C.R.; Macia, L. The Role of Short-Chain Fatty Acids in Health and Disease. *Adv. Immunol.* 2014, 121, 91–119. [Google Scholar]
33. Heng, B.C.; Aubel, D.; Fussenegger, M. An overview of the diverse roles of G-protein coupled receptors (GPCRs) in the pathophysiology of various human diseases. *Biotechnol. Adv.* 2013, 31, 1676–1694. [Google Scholar] [CrossRef]
34. Tazoe, H.; Otomo, Y.; Kaji, I.; Tanaka, R.; Karaki, S.-I.; Kuwahara, A. Roles of short-chain fatty acids receptors, GPR41 and GPR43 on colonic functions. *J. Physiol. Pharmacol.* 2008, 59, 251–262. [Google Scholar]
35. Galland, L. The Gut Microbiome and the Brain. *J. Med. Food* 2014, 17, 1261–1272. [Google Scholar] [CrossRef]
36. Kimura, I.; Inoue, D.; Maeda, T.; Hara, T.; Ichimura, A.; Miyauchi, S.; Kobayashi, M.; Hirasawa, A.; Tsujimoto, G. Short-chain fatty acids and ketones directly regulate sympathetic nervous system via G protein-coupled receptor 41 (GPR41). *Proc. Natl. Acad. Sci. USA* 2011, 108, 8030–8035. [Google Scholar] [CrossRef]
37. Nankova, B.B.; Agarwal, R.; Macfabe, D.F.; La Gamma, E.F. Enteric Bacterial Metabolites Propionic and Butyric Acid Modulate Gene Expression, Including CREB-Dependent Catecholaminergic Neurotransmission, in PC12 Cells - Possible Relevance to Autism Spectrum Disorders. *PLoS ONE* 2014, 9, e103740. [Google Scholar] [CrossRef]
38. Engel, P.; Moran, N.A. The gut microbiota of insects – diversity in structure and function. *FEMS Microbiol. Rev.* 2013, 37, 699–735. [Google Scholar] [CrossRef]
39. Nankova, B.B.; Agarwal, R.; Macfabe, D.F.; La Gamma, E.F. Enteric Bacterial Metabolites Propionic and Butyric Acid Modulate Gene Expression, Including CREB-Dependent Catecholaminergic Neurotransmission, in PC12 Cells - Possible Relevance to Autism Spectrum Disorders. *PLoS ONE* 2014, 9, e103740. [Google Scholar] [CrossRef]
40. Martinson, V.G.; Danforth, B.N.; Minckley, R.L.; Ruepell, O.; Tingek, S.; Moran, N.A. A simple and distinctive microbiota associated with honey bees and bumble bees. *Mol. Ecol.* 2011, 20, 619–628. [Google Scholar] [CrossRef] [PubMed]

41. Alberoni, D.; Baffoni, L.; Gaggia, F.; Ryan, P.; Murphy, K.; Ross, P.; Stanton, C.; Di Gioia, D. Impact of beneficial bacteria supplementation on the gut microbiota, colony development and productivity of *Apis mellifera* L. *Benef. Microbes* 2018, 9, 269–278. [Google Scholar] [CrossRef] [PubMed]
42. Grieneisen, L.E.; Livermore, J.; Alberts, S.; Tung, J.; Archie, E.A. Group Living and Male Dispersal Predict the Core Gut Microbiome in Wild Baboons. *Integr. Comp. Biol.* 2017, 57, 770–785. [Google Scholar] [CrossRef] [PubMed]
43. Buffington, S.A.; Di Prisco, G.V.; Auchtung, T.A.; Ajami, N.J.; Petrosino, J.F.; Costa-Mattioli, M. Microbial Reconstitution Reverses Maternal Diet-Induced Social and Synaptic Deficits in Offspring. *Cell* 2016, 165, 1762–1775. [Google Scholar] [CrossRef] [PubMed]
44. Varian, B.J.; Poutahidis, T.; DiBenedictis, B.T.; Levkovich, T.; Ibrahim, Y.; Didyk, E.; Shikhman, L.; Cheung, H.K.; Hardas, A.; Ricciardi, C.E.; et al. Microbial lysate upregulates host oxytocin. *Brain Behav. Immun.* 2017, 61, 36–49. [Google Scholar] [CrossRef] [PubMed]
45. O’Hara, A.M.; Shanahan, F. The gut flora as a forgotten organ. *EMBO Rep.* 2006, 7, 688–693. [Google Scholar] [CrossRef]
46. Gosselin, D.; Rivest, S. MyD88 signaling in brain endothelial cells is essential for the neuronal activity and glucocorticoid release during systemic inflammation. *Mol. Psychiatry* 2008, 13, 480–497. [Google Scholar] [CrossRef]
47. Sudo, N.; Chida, Y.; Aiba, Y.; Sonoda, J.; Oyama, N.; Yu, X.-N.; Kubo, C.; Koga, Y. Postnatal microbial colonization programs the hypothalamic-pituitary-adrenal system for stress response in mice. *J. Physiol.* 2004, 558, 263–275. [Google Scholar] [CrossRef]
48. Neufeld, K.M.; Kang, N.; Bienenstock, J.; Foster, J.A. Reduced anxiety-like behavior and central neurochemical change in germ-free mice. *Neurogastroenterol. Motil.* 2011, 23, 255-e119. [Google Scholar] [CrossRef]
49. Bailey, M.T.; Dowd, S.E.; Galley, J.D.; Hufnagle, A.R.; Allen, R.G.; Lyte, M. Exposure to a social stressor alters the structure of the intestinal microbiota: Implications for stressor-induced immunomodulation. *Brain Behav. Immun.* 2011, 25, 397–407. [Google Scholar] [CrossRef]
50. Zilber-Rosenberg, I.; Rosenberg, E. Role of microorganisms in the evolution of animals and plants: The hologenome theory of evolution. *FEMS Microbiol. Rev.* 2008, 32, 723–735. [Google Scholar] [CrossRef] [PubMed]
51. Shropshire, J.D.; Bordenstein, S.R. Speciation by Symbiosis: The Microbiome and Behavior. *mBio* 2016, 7, e01785-15. [Google Scholar] [CrossRef] [PubMed]
52. Bordenstein, S.R.; Theis, K.R. Host Biology in Light of the Microbiome: Ten Principles of Holobionts and Hologenomes. *PLoS Biol.* 2015, 13, e1002226. [Google Scholar] [CrossRef] [PubMed]

53. Theis, K.R.; Venkataraman, A.; Dycus, J.A.; Koonter, K.D.; Schmitt-Matzen, E.N.; Wagner, A.P.; Holekamp, K.E.; Schmidt, T.M. Symbiotic bacteria appear to mediate hyena social odors. *Proc. Natl. Acad. Sci. USA* 2013, 110, 19832–19837. [Google Scholar] [CrossRef] [PubMed]
54. Li, Q.; Korzan, W.J.; Ferrero, D.M.; Chang, R.B.; Roy, D.S.; Buchi, M.; Lemon, J.K.; Kaur, A.W.; Stowers, L.; Fendt, M.; et al. Synchronous Evolution of an Odor Biosynthesis Pathway and Behavioral Response. *Curr. Biol.* 2013, 23, 11–20. [Google Scholar] [CrossRef] [PubMed]
55. Chafee, M.E.; Zecher, C.N.; Gourley, M.L.; Schmidt, V.T.; Chen, J.H.; Bordenstein, S.R.; Clark, M.E.; Bordenstein, S.R. Decoupling of Host–Symbiont–Phage Coadaptations Following Transfer Between Insect Species. *Genetics* 2010, 187, 203–215. [Google Scholar] [CrossRef]
56. Tung, J.; Barreiro, L.B.; Burns, M.B.; Grenier, J.-C.; Lynch, J.; Grieneisen, L.E.; Altmann, J.; Alberts, S.C.; Blekhman, R.; Archie, E.A. Social networks predict gut microbiome composition in wild baboons. *eLife* 2015, 4, e05224. [Google Scholar] [CrossRef]
57. Phillips, J.G.P. The Treatment of Melancholia by the Lactic Acid Bacillus. *J. Ment. Sci.* 1910, 56, 422–430. [Google Scholar] [CrossRef]
58. Duerkop, B.A.; Vaishnava, S.; Hooper, L.V. Immune Responses to the Microbiota at the Intestinal Mucosal Surface. *Immunology* 2009, 31, 368–376. [Google Scholar] [CrossRef]
59. Heumann, D.; Barras, C.; Severin, A.; Glauser, M.P.; Tomasz, A. Gram-positive cell walls stimulate synthesis of tumor necrosis factor alpha and interleukin-6 by human monocytes. *Infect. Immun.* 1994, 62, 2715–2721. [Google Scholar] [CrossRef]
60. Alam, N.; McGinty, D.; Bashir, T.; Kumar, S.; Imeri, L.; Opp, M.R.; Szymusiak, R. Interleukin-1beta modulates state-dependent discharge activity of preoptic area and basal forebrain neurons: Role in sleep regulation. *Eur. J. Neurosci.* 2004, 20, 207–216. [Google Scholar] [CrossRef] [PubMed]
61. Schuld, A.; Haack, M.; Hinze-Selch, D.; Mullington, J.; Pollmacher, T. Experimentelle Untersuchungen der Interaktion zwischen Schlaf und Immunsystem beim Menschen. *PPmP-Psychother. Psychosom. Med. Psychol.* 2005, 55, 29–35. [Google Scholar] [CrossRef] [PubMed]
62. Kubota, T.; Fang, J.; Brown, R.A.; Krueger, J.M. Interleukin-18 promotes sleep in rabbits and rats. *Am. J. Physiol. Integr. Comp. Physiol.* 2001, 281, R828–R838. [Google Scholar] [CrossRef] [PubMed]
63. Cermakian, N.; Lange, T.; Golombek, D.; Sarkar, D.; Nakao, A.; Shibata, S.; Mazzoccoli, G. Crosstalk between the circadian clock circuitry and the immune system. *Chrono- Int.* 2013, 30, 870–888. [Google Scholar] [CrossRef] [PubMed]
64. Yang, J.-Y.; Huang, J.-W.; Chiang, C.-K.; Pan, C.-C.; Wu, K.-D.; Tsai, T.-J.; Chen, W.-Y. Higher plasma interleukin-18 levels associated with poor quality of sleep in peritoneal dialysis patients. *Nephrol. Dial. Transplant.* 2007, 22, 3606–3609. [Google Scholar] [CrossRef] [PubMed]

65. Grigoleit, J.-S.; Kullmann, J.S.; Wolf, O.T.; Hammes, F.; Wegner, A.; Jablonowski, S.; Engler, H.; Gizewski, E.R.; Oberbeck, R.; Schedlowski, M. Dose-Dependent Effects of Endotoxin on Neurobehavioral Functions in Humans. *PLoS ONE* 2011, 6, e28330. [Google Scholar] [CrossRef]
66. Matsuda, Y.; Ozawa, N.; Shinozaki, T.; Wakabayashi, K.-I.; Suzuki, K.; Kawano, Y.; Ohtsu, I.; Tatebayashi, Y. Ergothioneine, a metabolite of the gut bacterium *Lactobacillus reuteri*, protects against stress-induced sleep disturbances. *Transl. Psychiatry* 2020, 10, 1–11. [Google Scholar] [CrossRef]
67. Matsuda, Y.; Ozawa, N.; Shinozaki, T.; Aoki, K.; Nihonmatsu-Kikuchi, N.; Shinba, T.; Tatebayashi, Y. Chronic antidepressant treatments rescue reduced REM sleep theta power in a rat social defeat stress model of depression. *bioRxiv* 2020. [Google Scholar] [CrossRef]
68. Leclercq, S.; Matamoros, S.; Cani, P.D.; Neyrinck, A.M.; Jamar, F.; Stärkel, P.; Windey, K.; Tremaroli, V.; Bäckhed, F.; Verbeke, K.; et al. Intestinal permeability, gut-bacterial dysbiosis, and behavioral markers of alcohol-dependence severity. *Proc. Natl. Acad. Sci. USA* 2014, 111, E4485–E4493. [Google Scholar] [CrossRef]
69. Alzheimer’s Association 2016 Alzheimer’s disease facts and figures. *Alzheimer’s Dement.* 2016, 12, 459–509. [CrossRef]
70. Braak, H.; Braak, E. Neuropathological stageing of Alzheimer-related changes. *Acta Neuropathol.* 1991, 82, 239–259. [Google Scholar] [CrossRef]
71. Tiraboschi, P.; Hansen, L.A.; Thal, L.J.; Corey-Bloom, J. The importance of neuritic plaques and tangles to the development and evolution of AD. *Neurology* 2004, 62, 1984–1989. [Google Scholar] [CrossRef] [PubMed]
72. Hardy, J.; Higgins, G.A.; Mayford, M.; Barzilai, A.; Keller, F.; Schacher, S.; Kandel, E. Alzheimer’s disease: The amyloid cascade hypothesis. *Science* 1992, 256, 184–185. [Google Scholar] [CrossRef]
73. Yankner, B.; Duffy, L.K.; Kirschner, D.A. Neurotrophic and neurotoxic effects of amyloid beta protein: Reversal by tachykinin neuropeptides. *Science* 1990, 250, 279–282. [Google Scholar] [CrossRef]
74. Bachurin, S.O.; Gavrilova, S.I.; Samsonova, A.; Barreto, G.E.; Aliev, G. Mild cognitive impairment due to Alzheimer disease: Contemporary approaches to diagnostics and pharmacological intervention. *Pharmacol. Res.* 2018, 129, 216–226. [Google Scholar] [CrossRef] [PubMed]
75. Wyss-Coray, T.; Rogers, J. Inflammation in Alzheimer Disease--A Brief Review of the Basic Science and Clinical Literature. *Cold Spring Harb. Perspect. Med.* 2012, 2, a006346. [Google Scholar] [CrossRef] [PubMed]
76. Cappellano, G.; Carecchio, M.; Fleetwood, T.; Magistrelli, L.; Cantello, R.; Dianzani, U.; Comi, C.A.M. Immunity and inflammation in neurodegenerative diseases. *Am. J. Neurodegener. Dis.*

- 2013, 2, 89–107. [Google Scholar]
77. Ma, Q.; Xing, C.; Long, W.; Wang, H.Y.; Liu, Q.; Wang, R.-F. Impact of microbiota on central nervous system and neurological diseases: The gut-brain axis. *J. Neuroinflammation* 2019, 16, 1–14. [Google Scholar] [CrossRef]
78. Papassotiropoulos, A.; Lambert, J.-C.; Vrièze, F.W.-D.; Wollmer, M.; Von Der Kammer, H.; Streffer, J.R.; Maddalena, A.; Huynh, K.-D.; Wolleb, S.; Lütjohann, D.; et al. Cholesterol 25-Hydroxylase on Chromosome 10q Is a Susceptibility Gene for Sporadic Alzheimer's Disease. *Neurodegener. Dis.* 2005, 2, 233–241. [Google Scholar] [CrossRef]
79. Wozniak, M.; Frost, A.L.; Itzhaki, R.F. Alzheimer's Disease-Specific Tau Phosphorylation is Induced by Herpes Simplex Virus Type 1. *J. Alzheimer's Dis.* 2009, 16, 341–350. [Google Scholar] [CrossRef]
80. Stojković, D.; Kostić, M.; Smiljković, M.; Aleksić, M.; Vasiljević, P.; Nikolić, M.; Soković, M. Linking Antimicrobial Potential of Natural Products Derived from Aquatic Organisms and Microbes Involved in Alzheimer's Disease - A Review. *Curr. Med. Chem.* 2020, 27, 4372–4391. [Google Scholar] [CrossRef] [PubMed]
81. Lim, C.; Hammond, C.J.; Hingley, S.T.; Balin, B.J. *Chlamydia pneumoniae* infection of monocytes in vitro stimulates innate and adaptive immune responses relevant to those in Alzheimer's disease. *J. Neuroinflammation* 2014, 11, 1–11. [Google Scholar] [CrossRef] [PubMed]
82. Vogt, N.M.; Romano, K.A.; Darst, B.F.; Engelman, C.D.; Johnson, S.C.; Carlsson, C.M.; Asthana, S.; Blennow, K.; Zetterberg, H.; Bendlin, B.B.; et al. The gut microbiota-derived metabolite trimethylamine N-oxide is elevated in Alzheimer's disease. *Alzheimer's Res. Ther.* 2018, 10, 1–8. [Google Scholar] [CrossRef] [PubMed]
83. Harach, T.; Marungruang, N.; Duthilleul, N.; Cheatham, V.; Mc Coy, K.D.; Frisoni, G.B.; Neher, J.J.; Fåk, F.; Jucker, M.; Lasser, T.; et al. Reduction of Abeta amyloid pathology in APPPS1 transgenic mice in the absence of gut microbiota. *Sci. Rep.* 2017, 7, srep41802. [Google Scholar] [CrossRef]
84. Minter, M.R.; Zhang, C.; Leone, V.; Ringus, D.L.; Zhang, X.; Oyler-Castrillo, P.; Musch, M.W.; Liao, F.; Ward, J.F.; Holtzman, D.M.; et al. Antibiotic-induced perturbations in gut microbial diversity influences neuro-inflammation and amyloidosis in a murine model of Alzheimer's disease. *Sci. Rep.* 2016, 6, 30028. [Google Scholar] [CrossRef]
85. Zhang, L.; Wang, Y.; Xiayu, X.; Shi, C.; Chen, W.; Song, N.; Fu, X.; Zhou, R.; Xu, Y.-F.; Huang, L.; et al. Altered Gut Microbiota in a Mouse Model of Alzheimer's Disease. *J. Alzheimer's Dis.* 2017, 60, 1241–1257. [Google Scholar] [CrossRef]
86. Cai, Z.; Hussain, M.D.; Yan, L.-J. Microglia, neuroinflammation, and beta-amyloid protein in Alzheimer's disease. *Int. J. Neurosci.* 2013, 124, 307–321. [Google Scholar] [CrossRef]

87. Gatz, M.; Mortimer, J.A.; Fratiglioni, L.; Johansson, B.; Berg, S.; Reynolds, C.A.; Pedersen, N.L. Potentially modifiable risk factors for dementia in identical twins. *Alzheimer's Dement.* 2006, 2, 110–117. [Google Scholar] [CrossRef]
88. Stein, P.S.; Desrosiers, M.; Donegan, S.J.; Yepes, J.F.; Kryscio, R.J. Tooth loss, dementia and neuropathology in the Nun Study. *J. Am. Dent. Assoc.* 2007, 138, 1314–1322. [Google Scholar] [CrossRef]
89. Noble, J.M.; Borrell, L.N.; Papapanou, P.N.; Elkind, M.S.V.; Scarmeas, N.; Wright, C.B. Periodontitis is associated with cognitive impairment among older adults: Analysis of NHANES-III. *J. Neurol. Neurosurg. Psychiatry* 2009, 80, 1206–1211. [Google Scholar] [CrossRef]
90. Stewart, R.; Sabbah, W.; Tsakos, G.; D'aiuto, F.; Watt, R.G. Oral Health and Cognitive Function in the Third National Health and Nutrition Examination Survey (NHANES III). *Psychosom. Med.* 2008, 70, 936–941. [Google Scholar] [CrossRef] [PubMed]
91. Paganini-Hill, A.; White, S.C.; Atchison, K.A. Dentition, Dental Health Habits, and Dementia: The Leisure World Cohort Study. *J. Am. Geriatr. Soc.* 2012, 60, 1556–1563. [Google Scholar] [CrossRef] [PubMed]
92. Kamer, A.R.; Pirraglia, E.; Tsui, W.; Rusinek, H.; Vallabhajosula, S.; Mosconi, L.; Yi, L.; McHugh, P.; Craig, R.G.; Svetcov, S.; et al. Periodontal disease associates with higher brain amyloid load in normal elderly. *Neurobiol. Aging* 2015, 36, 627–633. [Google Scholar] [CrossRef] [PubMed]
93. Cockburn, A.F.; Dehlin, J.M.; Ngan, T.; Crout, R.J.; Boskovic, G.; Denvir, J.; Primerano, D.A.; Plassman, B.; Wu, B.; Cuff, C.F. High throughput DNA sequencing to detect differences in the subgingival plaque microbiome in elderly subjects with and without dementia. *Investig. Genet.* 2012, 3, 19. [Google Scholar] [CrossRef] [PubMed]
94. Kamer, A.R.; Craig, R.G.; Pirraglia, E.; Dasanayake, A.P.; Norman, R.G.; Boylan, R.J.; Nehorayoff, A.; Glodzik, L.; Brys, M.; De Leon, M.J. TNF- α and antibodies to periodontal bacteria discriminate between Alzheimer's disease patients and normal subjects. *J. Neuroimmunol.* 2009, 216, 92–97. [Google Scholar] [CrossRef]
95. Stein, P.S.; Steffen, M.J.; Smith, C.; Jicha, G.; Ebersole, J.L.; Abner, E.; Dawson, D. Serum antibodies to periodontal pathogens are a risk factor for Alzheimer's disease. *Alzheimer's Dement.* 2012, 8, 196–203. [Google Scholar] [CrossRef]
96. Noble, J.M.; Scarmeas, N.; Celenti, R.S.; Elkind, M.S.V.; Wright, C.B.; Schupf, N.; Papapanou, P.N. Serum IgG Antibody Levels to Periodontal Microbiota Are Associated with Incident Alzheimer Disease. *PLoS ONE* 2014, 9, e114959. [Google Scholar] [CrossRef]
97. Hayashi, C.; Gudino, C.; Iii, F.G.; Genco, C. REVIEW: Pathogen-induced inflammation at sites distant from oral infection: Bacterial persistence and induction of cell-specific innate immune inflammatory pathways. *Mol. Oral Microbiol.* 2010, 25, 305–316. [Google Scholar] [CrossRef]

98. Fasano, A.; Visanji, N.P.; Liu, L.W.C.; Lang, A.E.; Pfeiffer, R.F. Gastrointestinal dysfunction in Parkinson's disease. *Lancet Neurol.* 2015, 14, 625–639. [Google Scholar] [CrossRef]
99. Braak, H.; Gai, W.P.; Del Tredici, K. Idiopathic Parkinson's disease: Possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. *J. Neural Transm.* 2003, 110, 517–536. [Google Scholar] [CrossRef]
100. Ruffmann, C.; Parkkinen, L. Gut Feelings About α -Synuclein in Gastrointestinal Biopsies: Biomarker in the Making? *Mov. Disord.* 2016, 31, 193–202. [Google Scholar] [CrossRef] [PubMed]
101. Tremlett, H.; Bauer, K.C.; Appel-Cresswell, S.; Finlay, B.B.; Waubant, E. The gut microbiome in human neurological disease: A review. *Ann. Neurol.* 2017, 81, 369–382. [Google Scholar] [CrossRef] [PubMed]
102. Beach, T.G.; Arizona Parkinson's Disease Consortium; Adler, C.H.; Sue, L.I.; Vedders, L.; Lue, L.; Iii, C.L.W.; Akiyama, H.; Caviness, J.N.; Shill, H.A.; et al. Multi-organ distribution of phosphorylated α -synuclein histopathology in subjects with Lewy body disorders. *Acta Neuropathol.* 2010, 119, 689–702. [Google Scholar] [CrossRef] [PubMed]
103. Hawkes, C.H.; Del Tredici, K.; Braak, H. Parkinson's disease: A dual-hit hypothesis. *Neuropathol. Appl. Neurobiol.* 2007, 33, 599–614. [Google Scholar] [CrossRef] [PubMed]
104. Svensson, E.; Horváth-Puhó, E.; Thomsen, R.W.; Djurhuus, J.C.; Pedersen, L.; Borghammer, P.; Sørensen, H.T. Vagotomy and subsequent risk of Parkinson's disease. *Ann. Neurol.* 2015, 78, 522–529. [Google Scholar] [CrossRef] [PubMed]
105. Forsyth, C.B.; Shannon, K.M.; Kordower, J.H.; Voigt, R.M.; Shaikh, M.; Jaglin, J.A.; Estes, J.D.; Dodiya, H.B.; Keshavarzian, A. Increased Intestinal Permeability Correlates with Sigmoid Mucosa α -Synuclein Staining and Endotoxin Exposure Markers in Early Parkinson's Disease. *PLoS ONE* 2011, 6, e28032. [Google Scholar] [CrossRef] [PubMed]
106. Sampson, T.R.; Debelius, J.W.; Thron, T.; Janssen, S.; Shastri, G.G.; Ilhan, Z.E.; Challis, C.; Schretter, C.E.; Rocha, S.; Grdinaru, V.; et al. Gut Microbiota Regulate Motor Deficits and Neuroinflammation in a Model of Parkinson's Disease. *Cell* 2016, 167, 1469–1480.e12. [Google Scholar] [CrossRef]
107. Scheperjans, F.; Aho, V.; Msc, P.A.B.P.; Koskinen, K.; Paulin, L.; Pekkonen, E.; Haapaniemi, E.; Kaakkola, S.; Eerola-Rautio, J.; Pohja, M.; et al. Gut microbiota are related to Parkinson's disease and clinical phenotype. *Mov. Disord.* 2015, 30, 350–358. [Google Scholar] [CrossRef]
108. Keshavarzian, A.; Green, S.J.; Engen, P.A.; Voigt, R.M.; Naqib, A.; Forsyth, C.B.; Mutlu, E.; Shannon, K.M. Colonic bacterial composition in Parkinson's disease. *Mov. Disord.* 2015, 30, 1351–1360. [Google Scholar] [CrossRef]

109. Hasegawa, S.; Goto, S.; Tsuji, H.; Okuno, T.; Asahara, T.; Nomoto, K.; Shibata, A.; Fujisawa, Y.; Minato, T.; Okamoto, A.; et al. Intestinal Dysbiosis and Lowered Serum Lipopolysaccharide-Binding Protein in Parkinson's Disease. *PLoS ONE* 2015, 10, e0142164. [Google Scholar] [CrossRef]
110. Unger, M.M.; Spiegel, J.; Dillmann, K.-U.; Grundmann, D.; Philippeit, H.; Bürmann, J.; Faßbender, K.; Schwierz, A.; Schäfer, K.-H. Short chain fatty acids and gut microbiota differ between patients with Parkinson's disease and age-matched controls. *Park. Relat. Disord.* 2016, 32, 66–72. [Google Scholar] [CrossRef] [PubMed]
111. Berer, K.; Krishnamoorthy, G. Microbial view of central nervous system autoimmunity. *FEBS Lett.* 2014, 588, 4207–4213. [Google Scholar] [CrossRef] [PubMed]
112. Wang, Y.; Kasper, L.H. The role of microbiome in central nervous system disorders. *Brain Behav. Immun.* 2014, 38, 1–12. [Google Scholar] [CrossRef] [PubMed]
113. Goverman, J.; Woods, A.; Larson, L.; Weiner, L.P.; Hood, L.; Zaller, D.M. Transgenic mice that express a myelin basic protein-specific T cell receptor develop spontaneous autoimmunity. *Cell* 1993, 72, 551–560. [Google Scholar] [CrossRef]
114. Lee, Y.K.; Menezes, J.S.; Umesaki, Y.; Mazmanian, S.K. Proinflammatory T-cell responses to gut microbiota promote experimental autoimmune encephalomyelitis. *Proc. Natl. Acad. Sci. USA* 2011, 108, 4615–4622. [Google Scholar] [CrossRef]
115. Berer, K.; Mues, M.; Koutrolos, M.; Al Rasbi, Z.; Boziki, M.; Johner, C.; Wekerle, H.; Krishnamoorthy, G. Commensal microbiota and myelin autoantigen cooperate to trigger autoimmune demyelination. *Nat. Cell Biol.* 2011, 479, 538–541. [Google Scholar] [CrossRef]
116. Ridaura, V.K.; Faith, J.J.; Rey, F.E.; Cheng, J.; Duncan, A.E.; Kau, A.L.; Griffin, N.W.; Lombard, V.; Henrissat, B.; Bain, J.R.; et al. Gut Microbiota from Twins Discordant for Obesity Modulate Metabolism in Mice. *Science* 2013, 341, 1241214. [Google Scholar] [CrossRef]
117. Biedermann, L.; Zeitz, J.; Mwinyi, J.; Sutter-Minder, E.; Rehman, A.; Ott, S.J.; Steurer-Stey, C.; Frei, A.; Frei, P.; Scharl, M.; et al. Smoking Cessation Induces Profound Changes in the Composition of the Intestinal Microbiota in Humans. *PLoS ONE* 2013, 8, e59260. [Google Scholar] [CrossRef]
118. Norman, J.M.; Handley, S.A.; Baldridge, M.T.; Droit, L.; Liu, C.Y.; Keller, B.C.; Kambal, A.; Monaco, C.L.; Zhao, G.; Fleshner, P.; et al. Disease-Specific Alterations in the Enteric Virome in Inflammatory Bowel Disease. *Cell* 2015, 160, 447–460. [Google Scholar] [CrossRef]
119. Kernbauer, E.; Ding, Y.; Cadwell, K. An enteric virus can replace the beneficial function of commensal bacteria. *Nat. Cell Biol.* 2014, 516, 94–98. [Google Scholar] [CrossRef]
120. Goodrich, J.K.; Waters, J.L.; Poole, A.C.; Sutter, J.L.; Koren, O.; Blekhman, R.; Beaumont, M.; Van Treuren, W.; Knight, R.; Bell, J.T.; et al. Human Genetics Shape the Gut Microbiome. *Cell*

- 2014, 159, 789–799. [Google Scholar] [CrossRef] [PubMed]
121. Markle, J.G.M.; Frank, D.N.; Mortin-Toth, S.; Robertson, C.E.; Feazel, L.M.; Rolle-Kampczyk, U.; Von Bergen, M.; McCoy, K.; MacPherson, A.J.; Danska, J.S. Sex Differences in the Gut Microbiome Drive Hormone-Dependent Regulation of Autoimmunity. *Science* 2013, 339, 1084–1088. [Google Scholar] [CrossRef] [PubMed]
122. Tremlett, H.; Fadrosh, D.W.; Faruqi, A.A.; Zhu, F.; Hart, J.; Roalstad, S.; Graves, J.; Lynch, S.; Waubant, E.; Centers, T.U.N.O.P.M. Gut microbiota in early pediatric multiple sclerosis: A case-control study. *Eur. J. Neurol.* 2016, 23, 1308–1321. [Google Scholar] [CrossRef] [PubMed]
123. Chen, J.; Chia, N.; Kalari, K.R.; Yao, J.Z.; Novotna, M.; Soldan, M.M.P.; Luckey, D.H.; Marietta, E.V.; Jeraldo, P.R.; Chen, X.; et al. Multiple sclerosis patients have a distinct gut microbiota compared to healthy controls. *Sci. Rep.* 2016, 6, 28484. [Google Scholar] [CrossRef]
124. Jangi, S.; Gandhi, R.; Cox, L.M.; Li, N.; Von Glehn, F.; Yan, R.; Patel, B.; Mazzola, M.A.; Liu, S.; Glanz, B.L.; et al. Alterations of the human gut microbiome in multiple sclerosis. *Nat. Commun.* 2016, 7, 12015. [Google Scholar] [CrossRef]
125. Miyake, S.; Kim, S.; Suda, W.; Oshima, K.; Nakamura, M.; Matsuoka, T.; Chihara, N.; Tomita, A.; Sato, W.; Kim, S.-W.; et al. Dysbiosis in the Gut Microbiota of Patients with Multiple Sclerosis, with a Striking Depletion of Species Belonging to Clostridia XIVa and IV Clusters. *PLoS ONE* 2015, 10, e0137429. [Google Scholar] [CrossRef]
126. Cantarel, B.L.; Waubant, E.; Chehoud, C.; Kuczynski, J.; DeSantis, T.Z.; Warrington, J.; Venkatesan, A.; Fraser, C.M.; Mowry, E.M. Gut Microbiota in Multiple Sclerosis: Possible influence of immunomodulators. *J. Investig. Med.* 2015, 63, 729–734. [Google Scholar] [CrossRef]
127. Rumah, K.R.; Linden, J.; Fischetti, V.A.; Vartanian, T. Isolation of *Clostridium perfringens* Type B in an Individual at First Clinical Presentation of Multiple Sclerosis Provides Clues for Environmental Triggers of the Disease. *PLoS ONE* 2013, 8, e76359. [Google Scholar] [CrossRef]
128. Gevers, D.; Kugathasan, S.; Denson, L.A.; Vázquez-Baeza, Y.; Van Treuren, W.; Ren, B.; Schwager, E.; Knights, D.; Song, S.J.; Yassour, M.; et al. The Treatment-Naive Microbiome in New-Onset Crohn’s Disease. *Cell Host Microbe* 2014, 15, 382–392. [Google Scholar] [CrossRef]
129. Sokol, H.; Pigneur, B.; Watterlot, L.; Lakhdari, O.; Bermúdez-Humarán, L.G.; Gratadoux, J.-J.; Blugeon, S.; Bridonneau, C.; Furet, J.-P.; Corthier, G.; et al. *Faecalibacterium prausnitzii* is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. *Proc. Natl. Acad. Sci. USA* 2008, 105, 16731–16736. [Google Scholar] [CrossRef]
130. Scher, J.U.; Sczesnak, A.; Longman, R.S.; Segata, N.; Ubeda, C.; Bielski, C.; Rostron, T.; Cerundolo, V.; Pamer, E.G.; Abramson, S.B.; et al. Expansion of intestinal *Prevotella copri* correlates with enhanced susceptibility to arthritis. *eLife* 2013, 2, e01202. [Google Scholar] [CrossRef] [PubMed]

131. Farrokhi, V.; Nemati, R.; Nichols, F.C.; Yao, X.; Anstadt, E.; Fujiwara, M.; Grady, J.J.; Wakefield, D.; Castro, W.; Donaldson, J.; et al. Bacterial lipodipeptide, Lipid 654, is a microbiome-associated biomarker for multiple sclerosis. *Clin. Transl. Immunol.* 2013, 2, e8. [Google Scholar] [CrossRef] [PubMed]
132. Branton, W.; Lu, J.; Surette, M.; Holt, R.; Lind, J.; Laman, J.; Power, C. Multiple sclerosis lesions show perturbations in cerebral microbiota. *Neurology* 2016. Available online: https://n.neurology.org/content/86/16_Supplement/S37.005.short (accessed on 25 October 2020).
133. Varrin-Doyer, M.; Bs, C.M.S.; Schulze-Topphoff, U.; Nelson, P.A.; Stroud, R.M.; Cree, B.A.C.; Zamvil, S.S. Aquaporin 4-specific T cells in neuromyelitis optica exhibit a Th17 bias and recognize Clostridium ABC transporter. *Ann. Neurol.* 2012, 72, 53–64. [Google Scholar] [CrossRef]
134. Cree, B.A.C.; Spencer, C.M.; Varrin-Doyer, M.; Baranzini, S.E.; Zamvil, S.S. Gut microbiome analysis in neuromyelitis optica reveals overabundance of Clostridium perfringens. *Ann. Neurol.* 2016, 80, 443–447. [Google Scholar] [CrossRef] [PubMed]
135. Banati, M.; Csecsei, P.; Kőszegi, É.; Nielsen, H.H.; Sütő, G.; Bors, L.; Trauninger, A.; Csépány, T.; Rozsa, C.; Jakab, G.; et al. Antibody response against gastrointestinal antigens in demyelinating diseases of the central nervous system. *Eur. J. Neurol.* 2013, 20, 1492–1495. [Google Scholar] [CrossRef] [PubMed]
136. Goehler, L.E.; Gaykema, R.P.; Opitz, N.; Reddaway, R.; Badr, N.; Lyte, M. Activation in vagal afferents and central autonomic pathways: Early responses to intestinal infection with *Campylobacter jejuni*. *Brain Behav. Immun.* 2005, 19, 334–344. [Google Scholar] [CrossRef]
137. Cassuto, J.; Siewert, A.; Jodal, M.; Lundgren, O. The involvement of intramural nerves in cholera toxin induced intestinal secretion. *Acta Physiol. Scand.* 1983, 117, 195–202. [Google Scholar] [CrossRef]
138. Farthing, M. Enterotoxins and the enteric nervous system — a fatal attraction. *Int. J. Med. Microbiol.* 2000, 290, 491–496. [Google Scholar] [CrossRef]
139. Koussoulas, K.; Gwynne, R.M.; Foong, J.P.P.; Bornstein, J.C. Cholera Toxin Induces Sustained Hyperexcitability in Myenteric, but Not Submucosal, AH Neurons in Guinea Pig Jejunum. *Front. Physiol.* 2017, 8. [Google Scholar] [CrossRef]
140. Popoff, M.R.; Poulain, B. Bacterial Toxins and the Nervous System: Neurotoxins and Multipotential Toxins Interacting with Neuronal Cells. *Toxins* 2010, 2, 683–737. [Google Scholar] [CrossRef]
141. Rolfe, V.E.; Levin, R.J. Vagotomy inhibits the jejunal fluid secretion activated by luminal ileal *Escherichia coli* STa in the rat in vivo. *Gut* 1999, 44, 615–619. [Google Scholar] [CrossRef] [PubMed]

142. Rolfe, V.; Levin, R.J. Enterotoxin *Escherichia coli* STa activates a nitric oxide-dependent myenteric plexus secretory reflex in the rat ileum. *J. Physiol.* 1994, 475, 531–537. [Google Scholar] [CrossRef] [PubMed]
143. Eklund, S.; Jodal, M.; Lundgren, O. The enteric nervous system participates in the secretory response to the heat stable enterotoxins of *Escherichia coli* in rats and cats. *Neurosci.* 1985, 14, 673–681. [Google Scholar] [CrossRef]
144. Pothoulakis, C.; Castagliuolo, I.; Lamont, J.T. Nerves and Intestinal Mast Cells Modulate Responses to Enterotoxins. *News Physiol. Sci. Int. J. Physiol. Prod. Jointly Int. Union Physiol. Sci. Am. Physiol. Soc.* 1998, 13, 58–63. [Google Scholar] [CrossRef]
145. Kelly, C.P.; Becker, S.; Linevsky, J.K.; Joshi, M.A.; O'Keane, J.C.; Dickey, B.F.; Lamont, J.T.; Pothoulakis, C. Neutrophil recruitment in *Clostridium difficile* toxin A enteritis in the rabbit. *J. Clin. Investig.* 1994, 93, 1257–1265. [Google Scholar] [CrossRef]
146. Castagliuolo, I.; Lamont, J.T.; Létourneau, R.; Kelly, C.; O'Keane, J.; Jaffer, A.; Theoharides, T.C.; Pothoulakis, C. Neuronal involvement in the intestinal effects of *Clostridium difficile* toxin A and *Vibrio cholerae* enterotoxin in rat ileum. *Gastroenterol.* 1994, 107, 657–665. [Google Scholar] [CrossRef]
147. Xia, Y.; Hu, H.Z.; Liu, S.; Pothoulakis, C.; Wood, J.D. *Clostridium difficile* toxin A excites enteric neurones and suppresses sympathetic neurotransmission in the guinea pig. *Gut* 2000, 46, 481–486. [Google Scholar] [CrossRef]
148. Fettucciari, K.; Ponsini, P.; Gioè, D.; Macchioni, L.; Palumbo, C.; Antonelli, E.; Coaccioli, S.; Villanacci, V.; Corazzi, L.; Marconi, P.; et al. Enteric glial cells are susceptible to *Clostridium difficile* toxin B. *Cell. Mol. Life Sci.* 2016, 74, 1527–1551. [Google Scholar] [CrossRef]
149. Fettucciari, K.; Macchioni, L.; Davidescu, M.; Scarpelli, P.; Palumbo, C.; Corazzi, L.; Marchegiani, A.; Cerquetella, M.; Spaterna, A.; Marconi, P.; et al. *Clostridium difficile* toxin B induces senescence in enteric glial cells: A potential new mechanism of *Clostridium difficile* pathogenesis. *Biochim. Biophys. Acta Mol. Cell Res.* 2018, 1865, 1945–1958. [Google Scholar] [CrossRef]
150. Hu, D.-L.; Zhu, G.; Mori, F.; Omoe, K.; Okada, M.; Wakabayashi, K.; Kaneko, S.; Shinagawa, K.; Nakane, A. Staphylococcal enterotoxin induces emesis through increasing serotonin release in intestine and it is downregulated by cannabinoid receptor 1. *Cell. Microbiol.* 2007, 9, 2267–2277. [Google Scholar] [CrossRef]
151. Toh, M.; Moffitt, M.C.; Henrichsen, L.; Raftery, M.; Barrow, K.; Cox, J.M.; Marquis, C.P.; Neilan, B.A. Cereulide, the emetic toxin of *Bacillus cereus*, is putatively a product of nonribosomal peptide synthesis. *J. Appl. Microbiol.* 2004, 97, 992–1000. [Google Scholar] [CrossRef] [PubMed]
152. Klem, F.; Wadhwa, A.; Prokop, L.J.; Sundt, W.J.; Farrugia, G.; Camilleri, M.; Singh, S.; Grover, M. Prevalence, Risk Factors, and Outcomes of Irritable Bowel Syndrome After Infectious Enteritis: A

- Systematic Review and Meta-analysis. *Gastroenterol.* 2017, 152, 1042–1054.e1. [Google Scholar] [CrossRef]
153. Zanini, B.; Ricci, C.; Bandera, F.; Caselani, F.; Magni, A.; Laronga, A.M.; Lanzini, A. Incidence of Post-Infectious Irritable Bowel Syndrome and Functional Intestinal Disorders Following a Water-Borne Viral Gastroenteritis Outbreak. *Am. J. Gastroenterol.* 2012, 107, 891–899. [Google Scholar] [CrossRef] [PubMed]
154. Marshall, J.K.; Thabane, M.; Borgaonkar, M.R.; James, C. Postinfectious Irritable Bowel Syndrome After a Food-Borne Outbreak of Acute Gastroenteritis Attributed to a Viral Pathogen. *Clin. Gastroenterol. Hepatol.* 2007, 5, 457–460. [Google Scholar] [CrossRef] [PubMed]
155. Becker, L.; Nguyen, L.; Gill, J.; Kulkarni, S.; Pasricha, P.J.; Habtezion, A. Age-dependent shift in macrophage polarisation causes inflammation-mediated degeneration of enteric nervous system. *Gut* 2018, 67, 827–836. [Google Scholar] [CrossRef]
156. Gershon, A.A.; Chen, J.; Gershon, M.D. A Model of Lytic, Latent, and Reactivating Varicella-Zoster Virus Infections in Isolated Enteric Neurons. *J. Infect. Dis.* 2008, 197, S61–S65. [Google Scholar] [CrossRef]
157. Benini, L.; Sembenini, C.; Bulighin, G.M.; Polo, A.; Ederle, A.; Zambito, A.; Vantini, I. Achalasia: A Possible Late Cause of Postpolio Dysphagia. *Dig. Dis. Sci.* 1996, 41, 516–518. [Google Scholar] [CrossRef]
158. Debinski, H.S.; Kamm, M.A.; Talbot, I.C.; Khan, G.; Kangro, H.O.; Jeffries, D.J. DNA viruses in the pathogenesis of sporadic chronic idiopathic intestinal pseudo-obstruction. *Gut* 1997, 41, 100–106. [Google Scholar] [CrossRef]
159. Jucglà, A.; Badell, A.; Ballesta, C.; Arbizu, T. Colonic pseudo-obstruction: A complication of herpes zoster. *Br. J. Dermatol.* 1996, 134, 788–790. [Google Scholar] [CrossRef]
160. Gershon, A.A.; Chen, J.; Davis, L.; Krinsky, C.; Cowles, R.; Reichard, R.; Gershon, M. Latency of Varicella Zoster Virus in Dorsal Root, Cranial, and Enteric Ganglia in Vaccinated Children. *Trans. Am. Clin. Clim. Assoc.* 2012, 123, 17–35. [Google Scholar]
161. Gulbransen, B.D.; Sharkey, K.A. Novel functional roles for enteric glia in the gastrointestinal tract. *Nat. Rev. Gastroenterol. Hepatol.* 2012, 9, 625–632. [Google Scholar] [CrossRef] [PubMed]
162. Yu, Y.-B. Enteric glial cells and their role in the intestinal epithelial barrier. *World J. Gastroenterol.* 2014, 20, 11273–11280. [Google Scholar] [CrossRef] [PubMed]
163. Brun, P.; Giron, M.C.; Qesari, M.; Porzionato, A.; Caputi, V.; Zoppellaro, C.; Banzato, S.; Grillo, A.R.; Spagnol, L.; De Caro, R.; et al. Toll-Like Receptor 2 Regulates Intestinal Inflammation by Controlling Integrity of the Enteric Nervous System. *Gastroenterol.* 2013, 145, 1323–1333. [Google Scholar] [CrossRef] [PubMed]

164. Barajon, I.; Serrao, G.; Arnaboldi, F.; Opizzi, E.; Ripamonti, G.; Balsari, A.; Rumio, C. Toll-like Receptors 3, 4, and 7 Are Expressed in the Enteric Nervous System and Dorsal Root Ganglia. *J. Histochem. Cytochem.* 2009, 57, 1013–1023. [Google Scholar] [CrossRef] [PubMed]
165. Esposito, G.; Capoccia, E.; Gigli, S.; Pesce, M.; Bruzzese, E.; D'Alessandro, A.; Cirillo, C.; Di Cerbo, A.; Cuomo, R.; Seguella, L.; et al. HIV-1 Tat-induced diarrhea evokes an enteric glia-dependent neuroinflammatory response in the central nervous system. *Sci. Rep.* 2017, 7, 1–11. [Google Scholar] [CrossRef] [PubMed]
166. Esposito, G.; Capoccia, E.; Turco, F.; Palumbo, I.; Lu, J.; Steardo, A.; Cuomo, R.; Sarnelli, G.; Steardo, L. Palmitoylethanolamide improves colon inflammation through an enteric glia/toll like receptor 4-dependent PPAR- α activation. *Gut* 2013, 63, 1300–1312. [Google Scholar] [CrossRef] [PubMed]
167. Turco, F.; Sarnelli, G.; Cirillo, C.; Palumbo, I.; De Giorgi, F.; D'Alessandro, A.; Cammarota, M.; Giuliano, M.; Cuomo, R. Enteroglial-derived S100B protein integrates bacteria-induced Toll-like receptor signalling in human enteric glial cells. *Gut* 2013, 63, 105–115. [Google Scholar] [CrossRef] [PubMed]
168. Liñán-Rico, A.; Turco, F.; Ochoa-Cortes, F.; Harzman, A.; Needleman, B.J.; Arsenescu, R.; Abdel-Rasoul, M.; Fadda, P.; Grants, I.; Whitaker, E.; et al. Molecular Signaling and Dysfunction of the Human Reactive Enteric Glial Cell Phenotype: Implications for GI Infection, IBD, POI, Neurological, Motility, and GI Disorders. *Inflamm. Bowel Dis.* 2016, 22, 1812–1834. [Google Scholar] [CrossRef]
169. Brun, P.; Giron, M.C.; Zoppellaro, C.; Bin, A.; Porzionato, A.; De Caro, R.; Barbara, G.; Stanghellini, V.; Corinaldesi, R.; Zaninotto, G.; et al. Herpes Simplex Virus Type 1 Infection of the Rat Enteric Nervous System Evokes Small-Bowel Neuromuscular Abnormalities. *Gastroenterol.* 2010, 138, 1790–1801. [Google Scholar] [CrossRef]
170. Facco, M.; Brun, P.; Baesso, I.; Costantini, M.; Rizzetto, C.; Berto, A.; Baldan, N.; Pal, G.; Semenzato, G.; Castagliuolo, I.; et al. T Cells in the Myenteric Plexus of Achalasia Patients Show a Skewed TCR Repertoire and React to HSV-1 Antigens. *Am. J. Gastroenterol.* 2008, 103, 1598–1609. [Google Scholar] [CrossRef]
171. Khoury-Hanold, W.; Yordy, B.; Kong, P.; Kong, Y.; Ge, W.; Szigeti-Buck, K.; Ralevski, A.; Horvath, T.L.; Iwasaki, A. Viral Spread to Enteric Neurons Links Genital HSV-1 Infection to Toxic Megacolon and Lethality. *Cell Host Microbe* 2016, 19, 788–799. [Google Scholar] [CrossRef] [PubMed]
172. White, J.P.; Xiong, S.; Malvin, N.P.; Khoury-Hanold, W.; Heuckeroth, R.O.; Stappenbeck, T.S.; Diamond, M.S. Intestinal Dysmotility Syndromes following Systemic Infection by Flaviviruses. *Cell* 2018, 175, 1198–1212.e12. [Google Scholar] [CrossRef] [PubMed]

173. Mori, I. Viremic attack explains the dual-hit theory of Parkinson's disease. *Med. Hypotheses* 2017, 101, 33–36. [Google Scholar] [CrossRef] [PubMed]
174. Jang, H.; Boltz, D.; Sturm-Ramirez, K.; Shepherd, K.R.; Jiao, Y.; Webster, R.; Smeyne, R.J. Highly pathogenic H5N1 influenza virus can enter the central nervous system and induce neuroinflammation and neurodegeneration. *Proc. Natl. Acad. Sci. USA* 2009, 106, 14063–14068. [Google Scholar] [CrossRef] [PubMed]
175. Gesser, R.M.; Koo, S.C. Oral inoculation with herpes simplex virus type 1 infects enteric neuron and mucosal nerve fibers within the gastrointestinal tract in mice. *J. Virol.* 1996, 70, 4097–4102. [Google Scholar] [CrossRef] [PubMed]
176. Del Tredici, K.; Braak, H. Review: Sporadic Parkinson's disease: Development and distribution of α -synuclein pathology. *Neuropathol. Appl. Neurobiol.* 2016, 42, 33–50. [Google Scholar] [CrossRef] [PubMed]
177. Antonucci, A.; Fronzoni, L.; Cogliandro, L.; Cogliandro, R.F.; Caputo, C.; De Giorgio, R.; Pallotti, F.; Barbara, G.; Corinaldesi, R.; Stanghellini, V. Chronic intestinal pseudo-obstruction. *World J. Gastroenterol.* 2008, 14, 2953–2961. [Google Scholar] [CrossRef]
178. Déchelotte, P.J.; Mulliez, N.M.; Bouvier, R.J.; Vanlieféringen, P.C.; Lemery, D.J. Pseudo-Meconium Ileus Due to Cytomegalovirus Infection: A Report of Three Cases. *Pediatr. Pathol.* 1992, 12, 73–82. [Google Scholar] [CrossRef]
179. Besnard, M.; Faure, C.; Fromont-Hankard, G.; Ansart-Pirenne, H.; Peuchmaur, M.; Cezard, J.; Navarro, J. Intestinal pseudo-obstruction and acute pandysautonomia associated with epstein-barr virus infection. *Am. J. Gastroenterol.* 2000, 95, 280–284. [Google Scholar] [CrossRef]
180. Chang, A.E.; Young, N.A.; Reddick, R.L.; Orenstein, J.M.; Hosea, S.W.; Katz, P.; Brennan, M.F. Small bowel obstruction as a complication of disseminated varicella-zoster infection. *Surgery* 1978, 83, 371–374. [Google Scholar]
181. Vassallo, M.; Camilleri, M.; Caron, B.; Low, P.A. Gastrointestinal motor dysfunction in acquired selective cholinergic dysautonomia associated with infectious mononucleosis. *Gastroenterology* 1991, 100, 252–258. [Google Scholar] [CrossRef]
182. Selgrad, M.; De Giorgio, R.; Fini, L.; Cogliandro, R.F.; Williams, S.; Stanghellini, V.; Barbara, G.; Tonini, M.; Corinaldesi, R.; Genta, R.M.; et al. JC virus infects the enteric glia of patients with chronic idiopathic intestinal pseudo-obstruction. *Gut* 2009, 58, 25–32. [Google Scholar] [CrossRef] [PubMed]
183. Sarnelli, G.; Seguella, L.; Pesce, M.; Lu, J.; Gigli, S.; Bruzzese, E.; Lattanzi, R.; D'Alessandro, A.; Cuomo, R.; Steardo, L.; et al. HIV-1 Tat-induced diarrhea is improved by the PPARalpha agonist, palmitoylethanolamide, by suppressing the activation of enteric glia. *J. Neuroinflammation* 2018, 15, 94. [Google Scholar] [CrossRef] [PubMed]

184. Galligan, J.J. HIV, opiates, and enteric neuron dysfunction. *Neurogastroenterol. Motil.* 2015, 27, 449–454. [Google Scholar] [CrossRef]
185. Fitting, S.; Ngwainmbi, J.; Kang, M.; Khan, F.A.; Stevens, D.L.; Dewey, W.L.; Knapp, P.E.; Hauser, K.F.; Akbarali, H.I. Sensitization of enteric neurons to morphine by HIV-1 Tat protein. *Neurogastroenterol. Motil.* 2015, 27, 468–480. [Google Scholar] [CrossRef]
186. Guedia, J.; Brun, P.; Bhave, S.; Fitting, S.; Kang, M.; Dewey, W.L.; Hauser, K.F.; Akbarali, H.I. HIV-1 Tat exacerbates lipopolysaccharide-induced cytokine release via TLR4 signaling in the enteric nervous system. *Sci. Rep.* 2016, 6, 31203. [Google Scholar] [CrossRef]
187. Hansen, M.B.; Witte, A.-B. The role of serotonin in intestinal luminal sensing and secretion. *Acta Physiol.* 2008, 193, 311–323. [Google Scholar] [CrossRef]
188. Manocha, M.; Khan, W.I. Serotonin and GI Disorders: An Update on Clinical and Experimental Studies. *Clin. Transl. Gastroenterol.* 2012, 3, e13. [Google Scholar] [CrossRef]
189. Gershon, M. Review article: Roles played by 5-hydroxytryptamine in the physiology of the bowel. *Aliment. Pharmacol. Ther.* 1999, 13, 15–30. [Google Scholar] [CrossRef]
190. Bialowas, S.; Hagbom, M.; Nordgren, J.; Karlsson, T.; Sharma, S.; Magnusson, K.-E.; Svensson, L. Rotavirus and Serotonin Cross-Talk in Diarrhoea. *PLoS ONE* 2016, 11, e0159660. [Google Scholar] [CrossRef]
191. Hagbom, M.; De Faria, F.M.; Winberg, M.E.; Westerberg, S.; Nordgren, J.; Sharma, S.; Keita, Å.V.; Loitto, V.; Magnusson, K.-E.; Svensson, L. Neurotrophic Factors Protect the Intestinal Barrier from Rotavirus Insult in Mice. *mBio* 2020, 11. [Google Scholar] [CrossRef] [PubMed]
192. Westerberg, S.; Hagbom, M.; Rajan, A.; Loitto, V.; Persson, B.D.; Allard, A.; Nordgren, J.; Sharma, S.; Magnusson, K.-E.; Arnberg, N.; et al. Interaction of Human Enterochromaffin Cells with Human Enteric Adenovirus 41 Leads to Serotonin Release and Subsequent Activation of Enteric Glia Cells. *J. Virol.* 2018, 92. [Google Scholar] [CrossRef] [PubMed]
193. Esposito, G.; Pesce, M.; Seguella, L.; Sanseverino, W.; Lu, J.; Sarnelli, G. Can the enteric nervous system be an alternative entrance door in SARS-CoV2 neuroinvasion? *Brain, Behav. Immun.* 2020, 87, 93–94. [Google Scholar] [CrossRef] [PubMed]
194. Sambataro, G.; Giuffrè, M.; Sambataro, D.; Palermo, A.; Vignigni, G.; Cesareo, R.; Crimi, N.; Torrisi, S.E.; Vancheri, C.; Malatino, L.; et al. The Model for Early COvid-19 Recognition (MECOR) Score: A Proof-of-Concept for a Simple and Low-Cost Tool to Recognize a Possible Viral Etiology in Community-Acquired Pneumonia Patients during COVID-19 Outbreak. *Diagnostics* 2020, 10, 619. [Google Scholar] [CrossRef]
195. Giuffrè, M.; Di Bella, S.; Sambataro, G.; Zerbato, V.; Cavallaro, M.; Occhipinti, A.A.; Palermo, A.; Crescenzi, A.; Monica, F.; Luzzati, R.; et al. COVID-19-Induced Thrombosis in Patients without Gastrointestinal Symptoms and Elevated Fecal Calprotectin: Hypothesis Regarding Mechanism of

- Intestinal Damage Associated with COVID-19. *Trop. Med. Infect. Dis.* 2020, 5, 147. [Google Scholar] [CrossRef] [PubMed]
196. Giuffrè, M.; Bozzato, A.M.; Di Bella, S.; Occhipinti, A.A.; Martingano, P.; Cavallaro, M.F.M.; Luzzati, R.; Monica, F.; Cova, M.A.; Crocé, L.S. Spontaneous Rectal Perforation in a Patient with SARS-CoV-2 Infection. *J. Pers. Med.* 2020, 10, 157. [Google Scholar] [CrossRef]
197. Muller, P.A.; Koscsó, B.; Rajani, G.M.; Stevanovic, K.; Berres, M.-L.; Hashimoto, D.; Mortha, A.; Leboeuf, M.; Li, X.-M.; Mucida, D.; et al. Crosstalk between Muscularis Macrophages and Enteric Neurons Regulates Gastrointestinal Motility. *Cell* 2014, 158, 300–313. [Google Scholar] [CrossRef]
198. Gabanyi, I.; Muller, P.A.; Feighery, L.; Oliveira, T.Y.; Costapinto, F.A.; Mucida, D. Neuro-immune Interactions Drive Tissue Programming in Intestinal Macrophages. *Cell* 2016, 164, 378–391. [Google Scholar] [CrossRef]
199. Robinson, C.M.; Pfeiffer, J.K. Viruses and the Microbiota. *Annu. Rev. Virol.* 2014, 1, 55–69. [Google Scholar] [CrossRef]
200. Carding, S.R.; Davis, N.; Hoyles, L. Review article: The human intestinal virome in health and disease. *Aliment. Pharmacol. Ther.* 2017, 46, 800–815. [Google Scholar] [CrossRef]
201. Mukhopadhyay, I.; Segal, J.P.; Carding, S.R.; Hart, A.L.; Hold, G.L. The gut virome: The ‘missing link’ between gut bacteria and host immunity? *Ther. Adv. Gastroenterol.* 2019, 12.
202. Mukhopadhyay, I.; Segal, J.P.; Carding, S.R.; Hart, A.L.; Hold, G.L. The gut virome: The ‘missing link’ between gut bacteria and host immunity? *Ther. Adv. Gastroenterol.* 2019, 12.

Retrieved from <https://encyclopedia.pub/entry/history/show/15247>